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Abstract
3-Phenyl-2,3-dihydro-1,2-benzisothiazole 1,1 dioxide (NSC108406),
identified as an HIV-1 reverse transcriptase inhibitor, is chosen for lead
optimization. A series of analogues are docked using SYBYL FlexiDock into both
wild-type (wt) reverse transcriptase (RT) and Tyr181Cys181 (Y181C) RT, from
the dataset of efavirenz (Sustiva®) bound to the enzyme. Minimizations using
genetic algorithms are performed, and the lowest energy conformations are
evaluated. Five structures emerge as good fits either in both enzymes or only in
Y181C RT. 3-(m-Cyclopropylphenyl)- and 3-(isopropylfuranyl)-2-methyl-2,3dihydro-1,2-benzisothiazole 1,1-dioxides do not exhibit improved binding in wt RT
over efavirenz. In the Y181C pocket, the furanyl ring oxygen is oriented towards
Cys181, and the cyclopropyl group on the phenyl ring makes a strong contact
with Tyr183. Three 3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole
1,1-dioxides (ethynyl sultams) make very good contacts in both wt and Y181C
RT.
Synthesis of the ethynyl sultams is attempted using the appropriate
alkylethynyllithium reagents with saccharin, but 3,3-bisalkylethynyl-2,3-dihydro1,2-benzisothiazole 1,1-dioxides are the principal products. These are
methylated to give the bisalkylated sultams. When docked into wt RT, they are
consistently placed outside the pocket. In Y181C RT they make similar contacts
to nevirapine, a first-generation NNRTI.

ix

3-Chloro-1,2-benzisothiazole 1,1-dioxide is then coupled to the
alkylethynyllithium reagents to give the desired monosubstituted products.
(R,R)-N-(p-tolunesulfonyl)-1,2-diphenylethylenediamine-rhodium(pentamethycycopentadienyl)-Cl [(R,R)-TSDPEN-Rh-Cl], an enantioselective
catalyst for the reduction of imines, is used in an attempt to produce optically
active sultams; however, the products are not optically active. The cyclopropyland cyclobutylethynyl bonds are reduced to the corresponding alkanes. These
new cycloalkylethyl sultams, when docked into RT, exhibit a better fit in Y181C
than wt RT, similar to that of efavirenz.
In a study on the mechanism of the enantioselective reduction of 3-alkylor aryl-imines by (R,R)-TSDPEN-Rh-Cl, a number of imines are docked into the
catalyst cavity in two different approaches using the “original” approach that
gives the observed enantioselectivity and the “reverse” approach, which is
thought to give the opposite enantiomer. Molecular dynamic studies are carried
out. In all 3-(aryl/alkyl)imine sultams, an average of at least 10 kcal/mol energy
difference is observed between both approaches, showing probable structures
for the intermediate complex in the catalytic cycle that accounts product
stereochemistry.
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I. Introduction
A. AIDS—The Disease
Eighty million people are currently HIV (human immunodeficiency virus)
positive or living with acquired immunodeficiency syndrome (AIDS), and 20
million lives have already been lost to one of the deadliest diseases known to
man. Since its discovery, HIV has spread among 80 million people worldwide. A
total 900,000 of these reside in the US, while the rest live in Europe, Asia or
Africa, where the disease is rampant.1
In its early days, HIV was thought to target specific communities, such as
homosexuals and drug abusers. But now it is known that HIV does not
discriminate between woman, man or child, and it infects and causes AIDS using
the same mechanism of action across all races, cultures, classes and political
ranks. AIDS is not “a gay disease,” as it was dubbed earlier. It is largely a
sexually transmitted disease that has caused a widespread epidemic and a vast
public health problem that needs to be taken seriously on all levels. The war
against AIDS must continue on all battlefields from global and local political
legislation that provides prevention programs, health care, tests and medication
to all patients, to scientific research that facilitates the discovery and
development of new therapeutic candidates.
B. A Virus Discovered
Robert Gallo’s work on interleukin-2 (IL-2) growth factor paved the way for
his discovery of Human T-Cell Leukemia Virus Type 1 (HTLV-1). His work at the
1

time was unique and came along when there was a general misguided opinion
that human retroviruses do not exist and therefore do not cause cancer in
humans.2 After he isolated HTLV-1, independent studies out of Japan supported
his results and reported that HTLV-1 caused a leukemia endemic in Japan.
Gallo’s work in this field changed the view on human retroviruses, and in a way
played an important role in setting the stage for the discovery of the human
immunodeficiency virus (HIV).2
In the meantime, Luc Montagnier was leading a small virology division in
the Pasteur Institute in Paris. Montagnier and co-workers were also interested in
retroviruses that caused cancer. In 1982, using Gallo’s IL-2 growth factor
technique, they were able to isolate a viral DNA sequence from a breast cancer
patient biopsy, as well as from the patient’s T-cells. This viral DNA was also
similar to a sequence isolated from a mouse mammary cancer cell.3
In 1981 a report in the Morbidity and Mortality Weekly Report appeared
describing patients with no immunological response suffering from pneumocystic
pneumonia.1 Their blood samples showed no helper T-cells or CD4+ T-cells. As
more physicians across the US and the world became aware of this disease,
more reports of such patients came into the Center for Disease Control (CDC).1
By the summer of 1981 over 100 cases had been identified in the US, and all
were gay men. The new disease was dubbed “the gay disease.” Initially as the
CDC gathered epidemiological data, it was thought that lifestyle played a roll in
an individual’s susceptibility to contracting AIDS. Even a report from a physician
in Florida were both men and women of Haitian descent displayed similar
2

symptoms did not get rid of the lifestyle notion. Reports from France by Dr.
Rozenbaum and from Belgium by Dr. Piot of more AIDS patients started
emerging.1 Most interesting was the report of some Congolese patients in
Belgium exhibiting the same symptoms. In 1983 the CDC sent a team to the
Congo to look for patients with AIDS. There they found that men, women and
children were suffering from the disease. It was clear now that AIDS is not
necessarily a new disease, but a newly discovered one, and that this was a
worldwide health problem. Many questions needed to be answered. What
causes this disease? Where did it come from? And more importantly, where was
it going?
In the US more patients were being diagnosed with AIDS, but the patient
profile had changed. It was no longer gay men only who came in with the
symptoms, as intravenous drug users were exhibiting suppressed immune
response. Then a hemophiliac baby, who had several blood transfusions,
displayed loss of immune response and inability to breathe due to pneumonia.1
With this report, the CDC was now certain that AIDS is caused by a virus,
because a virus is the only particle small enough to pass through the different
filters used when donated blood is collected from different donors. They were
also sure that the blood supply was contaminated. More reports of hemophilia
patients developing AIDS started emerging. About 35,000 Americans had been
infected from contaminated blood and blood products.1
It is important to note here that by the time the first American patient was
diagnosed with AIDS, 250,000 more Americans were already infected. And by
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the time the first African patient was diagnosed, millions of Africans across the
continent were infected.1
Robert Gallo firmly believed that AIDS was caused by a human retrovirus
similar to HTLV. So his group decided to look for a retrovirus in blood cell
cultures. The problem was that their cell cultures died after a few days. They
were being consumed by the virus.2
In 1982 Francois Brun-Vezeinet, a former student of Montagnier and then
a member of the virology group in the Pasteur Institute initiated a collaborative
effort with Montagnier to find the cause of AIDS. Montagnier’s laboratory was
well equipped to hunt for lymphotropic retroviruses, so they obtained a lymph
node biopsy from a young gay man (a patient of Dr. Rozenbaum) and used it to
grow T-Cell cultures.3 Two weeks later, the cultures tested positive for reverse
transcriptase (RT) activity. At the time the only human retrovirus known was
HTLV, but the virus in Montagnier’s cell cultures tested negative for HTLV
antibody recognition and could not be precipitated. They were able to precipitate
it by using the patient’s own serum. More samples from different patients were
tested. Those with full-blown AIDS had a more aggressive form of the virus that
replicated rapidly and unlike HTLV killed the T-cell cultures. Finally they isolated
the virus and provided the first scanning electron microscopy (SEM) picture of
the human immunodeficiency virus (HIV).3 Montagnier and his colleagues knew
immediately that this virus was not the same as HTLV. Its morphology was
totally different. It had a cone-shaped center different than that of HTLV. The
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new virus pictures matched those of animal lentiviruses, which further confirmed
that this new virus does not belong to the HTLV genus.3
In the meantime Gallo’s team was still looking for an HTLV-related virus in
AIDS patients. SEM images of T-cell lines showed that AIDS patients had two
viruses. Gallo initially thought that one was a “mature” form of HTLV, the other
an “aberrant” form. However, with Montagnier’s publication of SEM images of
HIV, Gallo now knew that the reason many of his cell lines tested negative for
HTLV is because they were infected with a completely different virus, and that
the 5–10% HTLV-positive results came from patients infected with both HIV and
HTLV. In 1984 Gallo and co-workers submitted four papers that provided further
evidence that HIV is the causative agent of AIDS.2 Their work laid the
groundwork for the development of blood tests that could detect HIV. This halted
infection through blood transfusion and shed light on how much of the world’s
blood supply had been tainted by HIV-positive blood samples.
In 1987 azidothymidine (AZT) was the first anti-HIV drug to be approved
by the FDA for use by HIV patients.4 Today twenty different HIV drugs are
present on the market.5
C. The Origins of HIV: A Short Overview
HIV belongs to the lentivirus genus of which simian immunodeficiency
virus (SIV) is a part. There are five different lentiviurs lineages. HIV-1 and HIV-2
come from two different lineages. In genetic studies HIV-1 clusters with
chimpanzee SIV (SIVCPZ).6 Recent evidence suggests that the source of HIV-1 is
the chimpanzee subspecies P.t. troglodytes.7 HIV-2 clusters with Sooty
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Mangabeys SIV (SIVSM) and SIVMAC from macaques. Although SIVMAC was one
of the first SIV strains isolated, it was later discovered that all macaque infections
took place in captivity. Evolutionary evidence suggests that sooty mangabeys
are naturally infected by SIV and that they are the source of HIV-2.6 Other SIV
strains are African Green monkeys SIV (SIVAGM), Sykes monkeys SIV (SIVSYK),
l’Hoest monkeys SIV (SIVLHOEST), and Sun monkeys SIV (SIVSUN). All of these
SIV strains have cross-species transmissions as well.
Both HIV-1 and HIV-2 have genetic diversity. HIV-1 has three major
groups, M, N, O, and the M group has seven subtypes A–J. HIV-2 on the other
hand has six subtypes A–F. At least four independent cross-species
transmissions caused the formation of these subtypes.8, 9 The origins of HIV-1
and HIV-2 are still a highly debated topic. Initially the origins for both viruses
were estimated to date back as early as 1951,10 but other estimates suggested
that these viruses may have diverged as primates evolved putting the origin of
the lentivirus that infected the common ancestor of all apes and Old World
monkeys at 25 million years ago.11
A molecular clock model puts all three viruses, HIV-1, HIV-2 and SIVAGM,
with a common ancestor 150 years ago. A molecular clock model uses
information from different viruses isolated at various times. By comparing the
virus sequences and noting the different mutations, a rate of change can be
estimated. HIV-1 has three different proteins that evolved at different rates.
What the molecular clock model does not take into consideration is hostdependent evolution.6
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There is enough evidence that cross transmission causes lentiviruses to
evolve according to their host. SIVAGM is an example of a virus evolving
specifically with its host. There are four species of African Green Monkeys
dispersed throughout the African continent. They are the Sabaeus monkeys in
West Africa, the Tantalus monkeys in Central Africa, the Givets in East Africa,
and the Vervets from East to South Africa. Each species is naturally infected
with SIVAGM, and each clade (evolutionary class) of SIVAGM has its unique
evolutionary features, rates of evolution and divergence dates, further supporting
that as each species became infected with SIVAGM. The evolution of that specific
strain became independent of the others and more dependent on the host. It is
important to keep in mind that both SIV and HIV are parasites, and in order to
survive they need a host. So it is only common sense to expect them to evolve
along with their respective hosts. The common ancestor of African Green
Monkeys existed one million years ago, and it was probably naturally infected
with the common ancestor of SIVAGM.6
Another example of host-dependent evolution is that of SIVCPZ.
Chimpanzees are divided to four geographically distinct subspecies, and not
surprisingly SIVCPZ has four clades,6 each of these clades is specific to its
respective chimpanzee subspecies.12
The lack of a fossil record for viruses makes it impossible to rely on
conventional methods in estimating the age of HIV. In the molecular clock model
the estimation is based on rate of replication and rate of mutation calculations
without taking into consideration any other factors. The major weakness of this
7

model is that different viral sites may evolve at different rates so this makes
calculating and predicting the rate of evolution for the whole virus very difficult
and faulty. In more recent studies these rate differences were taken into
consideration, and the final estimation for SIV increased from 100 years to 350
years and for HIV from 50 years to 150 years. That is still inconsistent with the
idea of host-dependent evolution for millions of years. Sharp and co-workers
published estimations on the date of emergence for the HIV-1 M group.6 Their
initial work suggested a date around 1960,13 but the first HIV-1 positive blood
sample was collected in 1959 from a man from Zaire. The sequence of that virus
strain suggested an earlier date, possibly the 1940s.
D. HIV Lifecycle
1. Overview
HIV infection begins with binding of the viral envelope glycoproteins to the
CD4 receptor and one of the chemokine co-receptors, CXCR4 or CRC5 of the Tlymphocytes. This is followed by virus–cell fusion events that create a small
opening in the cell membrane through which the viral materials, which include
viral RNA and reverse transcriptase, are released into the cell. Once in the cell,
reverse transcription of the viral genome commences, followed by integration into
the cell genetic material. Viral particles are then synthesized within the cell
complete with a protein coat, and they are released into the body to further infect
other cells. Studies have shown that infection proceeds at a very rapid pace. In
one study it was apparent that viral DNA integration occurred approximately
seven hours after infection.14
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2. Viral entry
Viral entry into the host cell can be dissected into four major events: (i)
viral attachment to the cell surface, (ii) binding to the CD4 receptor, (iii)
interaction of the CD4-envelope glycoprotein complex with entry co-receptors
CRC5 and CCRX4, and (iv) virus–cell fusion.
The viral envelope glycoproteins gp120 and gp41 are essential for binding
and fusion with the host cell. Gp120 and gp41 are processed from the Nterminal and C-terminal parts of gp160. Gp120, the larger of the two molecules,
lies outside the envelope lipid bilayer and is responsible for binding with CD4
receptors and chemokine co-receptors and driving viral fusion.
The Gp120 amino-acid sequence consists of both conserved and variable
regions (V1–V5). V1–V4 are exposed loops with disulfide bonds at their base.
V1–V4 loops respond to antibody activity and are involved in gp120 binding to
CD4 receptors as well as chemokine receptors. V1–V3 are involved in coreceptor binding as well as virus–cell fusion.15 The V3 loop contains 35 amino
acids in between Cys303 and Cys338, which are joined together by a disulfide
bond. Mutations in the tip and stem of the V3 loop produced gp120 glycoproteins
able to bind to CD4 receptors but unable to form syncytia. V3 neutralizing
antibodies either completely blocked or greatly reduced the ability of HIV-1
infection.16 More important are mutations on the disulfide bond residues Cys303
and Cys338. These rendered gp120 completely inactive. Mutagenesis studies
indicate that deletion of the V3 loop from the viral env gene renders HIV
completely unable to process gp160 to both gp120 and gp41, as well as hinders
9

syncytia formation. The exact nature of interactions between V3 and the
CCR5/CXCR4 receptors is not completely understood; however, from the gp120
core crystal structure and other studies it can be assumed that electrostatic
interactions between the substrate and receptor do occur.17
Detailed crystal structures of gp120 bound and unbound to CD4 have
been published at resolutions as low as 2.5 Å.15, 18, 19 These structures have
provided more details on the complexity of the binding process, which will
hopefully lead to the design of anti-HIV binding compounds that can be used in
therapy. Although the exact structure of the V1/V2 and V3 loops is still not
completely resolved, the core structure of deglycosylated gp120 has been
determined, and the positioning of these three key loops can be deduced,
allowing for better understanding of their function. The crystal structure of the
gp120 core shows that it has two domains that provide the flexibility for receptorinduced conformational change. The gp120 protein backbone binds to the CD4
receptor. The antigenic side chains are not involved in this process. This allows
for the alteration of the amino acid side chains without altering the backbone, and
therefore limits loss of binding affinity to CD4. Such a feature gives HIV a rich
antigenic diversity allowing it to escape the immune system. Another binding
interaction is the “knob–socket” interaction between protruding amino acids in
CD4 and holes in gp120. Such interactions may be possible targets for
developing binding inhibitors.17
The heavy glycosylation of gp120 and gp41 proteins presents a challenge
to the immune system. Sugars present themselves in the body as “self”, thereby
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shielding the receptor binding domains of gp120 and not causing an antibody
response. They also reduce HIV-1 binding to immunoglobulin-like B-cell
receptors, which limits antibody production altogether.14, 19, 20
Another important feature in the gp120 binding mechanism is the
positioning of the V1/V2 and V3 loops. Although there are no crystal structures
available for these regions, modeling studies show them forming an umbrella that
shields the CD4 binding region of gp120. Presenting the V1/V2 and V3 regions
to the immune system protects HIV even further, because should an antibody
succeed in neutralizing these regions, the virus can simply mutate non-essential
residues and escape the immune response.15, 17, 19, 20
Gp41, the smaller of the two proteins, lies in the transmembrane (TM)
region and mediates virus–cell fusion as well as intracellular membrane fusion
(syncytia formation). Gp41 shares general structural features with other viral
fusion proteins: (a) the presence of an N-terminus containing a hydrophobic
glycine-rich amino acid sequence known as the fusion peptide (FP), and (b)
Heptad repeats (HR) adjacent to the TM domains and the hydrophobic
sequences. These are referred to as NHR for N-terminus heptad repeat and
CHR for C-terminus heptad repeats.21 The three NHRs fold into a coiled-coil
structure with the three CHRs fitting into the grooves, forming a thermostable sixhelix bundle. 22 The two termini are joined together by an extended loop.23-25 The
heptad repeat contains a reoccurring seven amino acid sequence (abcdefg) in
which the third and fifth positions contain a hydrophobic amino acid.

11

The HR sequence is highly conserved, and mutagenic studies have
shown that mutations in this region render HIV-1 unable to complete the
membrane-fusion process, and therefore are unable to infect the cell. This shows
the importance of gp41 in the viral infection/replication cycle.22
The fusion mechanism is a highly coordinated and regulated process that
ensures that specific protein lipid interactions will occur at the right time and
place. If the envelope proteins are activated too early or too late, the virus will be
unable to infect.22, 26
Gp120 binding to CD4 receptor signals the beginning of the viral fusion
reaction. Gp41 contains three immunogenic regions, two of which become
exposed after CD4 binding occurs. The first region is the loop connecting the
NHR’s and CHR’s and lie between residues 598 and 604, and the second is in
the CHR helix residues 644–663. The third region contains amino acids 656–671
and lies in the transmembrane domain.23, 27
More dramatic conformational changes are observed after co-receptor
binding occurs. Melikyan and co-workers showed that co-receptor binding is
necessary in order for fusion to proceed.28 The formation of the metastable sixhelix bundle overcomes a large energy barrier and brings the two membranes
closer together; however; lipid bilayer membranes have many repulsive forces
between them. To overcome this energy barrier gp41 drives this process by
presenting a hydrophobic region in its FP that inserts itself into the cellular
membrane causing it expand.22,23
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The fusion process has been shown to be multistep. In the first step the
outer monolayer is fused. In the second step a rupture of the inner monolayer
occurs creating a fusion part through which the viral materials pass into the
cellular cytoplasm. The FP stabilizes this complex; in a study a sequence of
amino acids taken from the FP were shown to encourage lipid mixing.23 Gp41 is
attached to the viral membrane by a transmembrane region; the TM is preceded
by a tryptophan-rich region. It is not clear how these tryptophan residues
contribute to the fusion process, but mutational studies have shown that this
region is important for successful fusion.22, 23, 29 Once the viral materials are in
the cell, reverse transcription begins.
3. Reverse Transcription
HIV has a total of nine genes encoded onto two identical strands of
genomic RNA. Following infection, one of these mRNA strands is converted to
viral materials through a process called reverse transcription. Initially a reverse
transcription initiation complex (RTIC) is formed. At the heart of reverse
transcription is HIV reverse transcriptase (RT), a heterodimer composed of p66
and p51 subunits.30 Both of these subunits are encoded by the viral pol gene,
and are expressed as one gp160 subunit. A viral aspartyl protease cleaves the
gp160 precursor into the functional heterodimer p51/p66. Both p66 and p51
subunits are essential in viral replication; together they form a stable dimer that is
able to carry DNA transcription to completion. Crystal structures have identified
two dimerization sites. The first one is a series of leucines between residues 283
and 310. The second is a series of conserved tryptophans in the connection
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subdomain between residues 399 and 414. In crystal structures of RT bound to
dsDNA, these tryptophan series in both dimers are in close proximity to each
other. Synthetic peptides derived from this region inhibit RT dimerization and
enzymatic activity.31
P66 resembles a right hand with a palm, fingers, thumb, and connection
domains (See Figure 1). It also contains the active site and the RNase H site in
its N-terminus and C-terminus, respectively. P51 is analogues to p66, but it lacks
the RNase H site (C-terminus) 31-34 P51 has no catalytic activity; its main function
is to provide structural support for p66. Crystal structures of bound and unbound
reverse transcriptase have shed some light on the conformational changes that
occur when the enzyme is bound to an inhibitor, to a double-stranded DNA
(dsDNA) and to a polypurine RNA:DNA double strand.33-39
Understanding the RT mechanism of action in its entirety is essential in
RT inhibitor design. The major conformational change between the bound and
unbound reverse transcriptase is the positioning of the thumb. In the unbound
RT, the thumb is in an upright position, in close proximity to the fingers
subdomains. Two main points of contact have been identified: a bond between
Arg78 in the fingers and the main chain of the thumb, and a nonpolar interaction
between Phe61 in the fingers subdomain and Leu289. These interactions are
small in size and weak in strength allowing the thumb freedom of movement to
make the necessary conformational changes.32 The RT/dsDNA and
RT/RNA:DNA complexes have the same conformations, with the fingers and
palm subdomains interacting heavily with the substrates present in the catalyti
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Figure 1. Reverse transcriptase bound to efavirenz in the allosteric binding
pocket (red) (pdb code 1ikw).
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palm subdomains interacting heavily with the substrates present in the
catalytic cavity.34, 39
It is clear that RT is a flexible enzyme able to undergo necessary
conformational changes during its catalytic activity. This feature of reverse
transcriptase makes it an attractive target for drug design. (For a detailed
discussion on NNRTI mechanism of action, refer to the non-nucleoside reverse
transcriptase inhibitors (NNRTI) section below.)`
DNA synthesis has three major steps that are catalyzed by RT: (i) RNAdependent DNA polymerization, where the RNA:DNA hybrid is formed, (ii) RNase
H degradation of the RNA template, (iii) DNA-dependent DNA polymerization; the
dsDNA is formed in this stage and is ready to be integrated into the host
genome.31, 36 Reverse transcription is initiated from the primer binding site
(PBS). PBS is comprised of an 18-nucleotide viral genome sequence.31 The
reverse transcription initiation complex (RTIC) is then formed. Its structure is still
not properly characterized; however, attempts to fully characterize it are
underway. HIV is a parasite, so naturally it would require assistance from its host
cell machinery to complete its replication cycle. For example, the RTIC is formed
outside the host cell nucleus; however, in order for DNA transcription to be
complete, the complex needs to be moved from the cytoplasm to the nucleus.
Other cellular proteins seem to regulate HIV replication. The cellular protein
barrier-to-autointegration factor (BAF) inhibits viral DNA from integration into
itself. The structure of BAF is still unidentified. Cellular DNA replication
processes are reprogrammed as early as 30 minutes after infection, which
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suggests some sort of communication resulting from viral binding to the CD4,
CCR5 and CCRX4 receptors. Once the new viral DNA strand is synthesized,
integration begins.31
4. Integration
Integration is essential for retroviral replication. The linear-strand DNA,
the product of reverse transcription, is the substrate for HIV-1 integrase. Once
replication is complete, a pre-integration complex forms. Isolates of this complex
contain viral DNA, reverse transcriptase, nucelopcapsid, integrase, and two
cellular proteins: high-mobility-group HMG-I(Y), and BAF (barrier-toautointegration factor). Retroviral pre-integration complexes either enter the
nucleus through the nuclear pore or wait until the nuclear membrane dissolves
during cellular division.40
Integrase binds to the viral DNA and cleaves its 3′-end groups, resulting in
the removal of two nucleotides from each end, a reaction called 3’-end
processing. The result is the exposure of the 3′-end hydroxyl groups where the
host DNA will be connected. The second step is the insertion of the exposed
viral DNA into cellular DNA. There is no site specificity for this integration step,
so it could occur anywhere on the cellular DNA. Both 3′-end processing and
DNA strand transfer occur by a one-step mechanism.41, 42 In 3′-end processing
water is used as a nucelophile. It is thought that DNA strand transfer occurs in a
similar fashion. Although both steps are chemically similar, their binding to the
integrase active site must be different, because in the DNA strand transfer, both
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viral and cellular DNA must be bound to the enzyme.40, 41, 43 The exact
mechanism of these two steps is still not very clear.
Unlike reverse transcriptase, a complete crystal structure of HIV-1
integrase has yet to be obtained. However, through protease digestion and
functional complementation studies, it was determined that HIV-1 integrase
contains three domains: the N-terminal domain, the catalytic core domain,and the
C-terminal domain. Each of these domain structures has been determined by
crystallography and NMR studies.44-46
The N-terminus consists of 50 amino acids between residues 1 and 50. It
is essential for integrase activity. The main residues involved in integration are
the four conserved amino acids His2Cys2; this motif is characteristic of zincbinding sites.40, 41, 43 Mutations to any of these residues reduce the N-terminus’s
ability to bind to zinc and greatly affect integrase activity. Crystal structures and
NMR structures have been determined; the N-terminal region has four helices,
stabilized by hydrophobic interactions in the upper region, and by the zinc ion in
the lower region.41
The C-terminus is the least conserved of all three domains. It is comprised
of 80 amino acids between residues 213 and 288. It binds DNA nonspecifically,
and its deletion leads to complete loss of 3’-end processing. NMR studies
showed a five-strand β-barrel.46, 47 It is not clear what the exact functions of the
N- and C-termini domains are in the integration reaction. Mutations to either
domain leads to low activity in the enzyme, or in some cases to complete
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inhibition. A complete crystal structure may help explain the functions of these
two domains.16
The catalytic core domain is the best characterized and studied of all three
domains. It is comprised of 162 amino acids lying between the residues 50 and
212.40, 43 It also contains the catalytic triad of acidic residues D, D–35-E. In HIV-1
integrase, this motif corresponds to Asp64, Asp116 and Glu152.41 Mutations in
this motif severely deplete or completely abolish integrase activity.41 X-ray
crystallography of the core domain revealed a five-strand β-sheet and six αhelices.48, 49 In the crystal structure the catalytic triad residues are in close
proximity to each other; they bind divalent metal ions either Mg2+ or Mn2+. The
other residues of the catalytic core region exhibit great flexibility, suggesting that
DNA binding is required to bring the triad into close contact with each other to
ensure proper metal binding. Metal binding is required for full integrase activity.
While crystal structures have shown metals bound in the catalytic site and in the
N-terminus, it is not clear if other metal binding sites are present.43 More studies
are required.
As mentioned above, each of the HIV-1 integrase domains have been well
characterized; however, there are no crystal structures of the three domains
together, bound or unbound to substrate DNA. Such a structure will help
understand the interactions between these domains and their effect on
integration.
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After integration, synthesis of the viral poly-protein is accomplished using
cellular machinery. Cleavage of this large poly-protein into viral proteins is
catalyzed by HIV protease.
5. Cleavage of Viral Proteins Catalyzed by Protease
HIV protease is a homodimer made up of 99 residues each. Although the
crystal structure on the unbound enzyme appears to be symmetrical, HIV
protease is an asymmetrical enzyme. In fact similar monomer regions are not
identical. The active site is located at the bottom of the dimerization site and is
covered by two flexible “flaps” of β-hairpins. The β-hairpin flexibility is necessary
for substrate binding and product release as well as inhibitor activity.50 Each
monomer contributes one of the catalytic aspartic acids. Each catalytic triad in
both monomers contains Asp25-Thr26-Gly27. Both triads are stabilized by a
hydrogen-bond network.51 And the aspartic acid residues are close to each other
in a coplanner position.52 The hydrolysis mechanism begins with activation of a
water molecule, followed with a nucleophilic attack by water on the scissile bond
to form a tetrahedral intermediate. The tetrahedral intermediate then breaks
down aided by proton transfer to give the desired amino and carboxylate
products.50
E. Anti-HIV Chemotherapy
The diversity of enzymes and receptors involved in the HIV lifecycle
present multiple targets for drug design. Perhaps one of the biggest challenges
in designing new anti-HIV compounds arises from its tendency to mutate at high
rates. HIV, particularly reverse transcriptase, is error prone with no correction
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mechanism set in place. Once patients are exposed to drugs that are active
against wild-type HIV, mutant strains that are resistant to therapy are selected.
As described above in detail, HIV infection begins with cell attachment and
binding to CD4 receptors, followed by co-receptor binding, virus–cell membrane
fusion, replication, integration and then synthesis of new viral particles. Each of
these processes has a specific enzyme or receptor, and each of these targets
can be considered for anti-HIV therapy.
Several anti-HIV compounds are being studied at different levels of
development. I have attempted to give a short review on the different inhibitors
present with a main focus on transcriptase inhibitors, in particular non-nucleoside
reverse transcriptase inhibitors (NNRTIs).
1. Cellular CD4 Receptor Down-Modulators
The CD4 receptor is the main target for HIV entry into the cell.
Cyclotriazadisulfonamide (CADA, see below) was shown to inhibit HIV infection
by down-modulating CD4 receptor expression on cell surfaces. CADA is specific
for CD4 down-modulation and does not affect other receptors such as CXCR4
and CCR5.53 It does not directly bind to the receptors, but appears to be involved
in the down-regulation of CD4 expression on cell surfaces.54 In a recent study
CADA exhibited the ability to work synergistically with other anti-HIV drugs such
as nucleoside reverse transcriptase inhibitors, non-nucleoside reverse
transcriptase inhibitors, nucleotide reverse transcriptase inhibitors and protease
inhibitors.55
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2. Virus Attachment Inhibitors
Mannose-specific plant lectins from Galanthus nivalis (GNA) and
Hippeastrum hybrid (HHA) have shown activity against viral envelope
glycoprotein gp120. Exposure to these lectins produced HIV strains with a
mutant gp120, but not gp41. These compounds (proteins) are unique in their
structure, are of low toxicity, and are currently being considered as microbicides
to be used topically.56, 57 Another potential microbicide is the protein cyanovirinN, an 11-kDa protein isolated from the cyanobacterium Nostoc ellipsosporum. It
has a unique affinity for gp120 and inhibits both CD4-dependent and independent binding.58-60 BSMS378806 {(4-benzoyl-1-[4-methoxy-1H-pyrrol[2,3b]pyridin-3-yl]oxoacetyl)-2-(R)-methylpiperazine}, another CD4 antagonist, has
been identified as a new class of HIV attachment inhibitors. It has exhibited
inactivity against CD4 independent viral entry, which suggests that it interferes
specifically with CD4–gp120 interactions. It has shown great bioavailability and
low toxicity in initial animal cell studies.61-63
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3. CXCR4 and CCR5 Antagonists
After CD4 binding, gp120 interacts with either CXCR4 or CCR5 receptors.
In clinical studies AMD3100, a bicyclam CXCR4 antagonist, exhibited inhibition
against X4 and X4/R5 HIV strains. A dose as low as 5 µg/kg/h in individuals with
X4 or X4/R5 resulted in complete loss of viral infection within ten days. Other
bicyclams are being pursued as potential candidates. QSAR studies revealed
that the presence of both macrocyclic cyclam rings is not necessary for anti-HIV
potency. AMD3465 has only once cyclam ring and still possesses comparable
potency against HIV as AMD3100.64, 65
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TAK779 is the first nonpeptidic CCR5 antagonist identified to block HIV infection
at nanomolar concentrations. Unfortunately, it has very low oral bioavailability
and causes severe irritation at the injection site.66 Further research led to the
discovery of the bioavailable TAK220. The structure of TAK220 is not yet
revealed 65
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SCH351125 was the first CCR5 antagonist advanced to clinical
studies. It has the ability to reduce viral load in patients not receiving any other
antiviral agents. SCH351125, SCH350581 and TAK779 bind to a putative
binding pocket in the TM helices 1, 2, 3 and 7.67-69
Two other CCR5 inhibitors worthy of mentioning are UK427857 and MRK1. UK427857 depletes viral load levels ten days after administration and
sustains these low levels ten days after therapy was stopped. It is already in
clinical trials and may become a once-a-week pill in HIV therapy. MRK-1 has
high potency against R5 HIV strains, and it showed great potential as a vaginal
microbicide gel for use against HIV-1 sexual transmission.70, 71
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4. Viral Cell Fusion Inhibitors
Following co-receptor binding, gp120 dissociates from the viral envelope
to expose gp41, which initiates the virus–cell membrane fusion process.
Enfuvirtide, also known as T-20, DF-178, and Fuzeon, is a synthetic 36-amino
acid peptide corresponding with residues 127–162 of gp41. Initial clinical trials
—supported by later studies in North America, South America and Europe—
showed the ability of this peptide to lower viral load by 1.5–2.0 fold during 15
days of treatment.72 Unfortunately Enfuviritide has to be administered through an
injection twice daily and causes injection-site irritation. It is also worth noting that
large-scale peptide synthesis is costly.73, 74

5. HIV Integrase Inhibitors
There is no known cellular homologue for HIV integrase; therefore, this is
potentially a good therapeutic target. The structure of the HIV integrase core
domain complexed with an inhibitor was described recently, leading to the design
of several diketoacids such as L-708, 906 and L-731,988, which act as inhibitors
for the covalent bond formation between the 3′-end of viral DNA and cellular
DNA. In a study these inhibitors were able to stop infection after seven hours.
This further supports their involvement in the later stages of HIV replication.75
Unfortunately, repeated exposure to these diketoacids resulted in mutant
integrase strains.76, 77
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6. HIV Protease Inhibitors
HIV protease is responsible for the cleavage of viral precursor
polyproteins to the structural proteins: p17, p24, p7, p6, p2, p1, and the functional
proteins: protease (p11), RT (p51/p66) and integrase (p32). Protease inhibitors
stop this process and prevent the formation of the viral particles. The protease
inhibitors currently approved for therapy carry the same structural feature, a
hydroxyethylene bond.65 Astanavir, an aza-dipeptide analogue was approved for
marketing by the FDA in 2003. It displayed a favorable profile to resistant PI
strains.78, 79
The most recently approved PI by the FDA is darunavir (TMC-114), which
was developed by structure-based design studies. The main objective of these
studies was to design a drug that retains its activity against multidrug-resistant
(MDR) viruses.

GRL-02031 is another analogue of darunavir coming from the

same group that developed the other two PIs. The structure of this latest
compound has not been revealed. Darunavir was approved for use in MDR
patients who are unresponsive to other AIDS drugs.
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7. Reverse Transcriptase Inhibitors:
(a) Nucleoside/Nucleotide reverse transcriptase Inhibitors (NRTIs, NtRTIs).
Upon conversion to their triphosphate form, they inhibit RT competitively
by causing chain termination. They cause mutations in RT, for example
some Zidovudine (AZT) resistant RTs are capable of removing the
blocked primer from the active site.80,81
(b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): NNRTIs are
structurally diverse. They bind to an allosteric pocket 10–15 Å away from the
active site and cause conformational changes in the enzyme, rendering it
inactive. Molecular modeling studies have been used extensively in the
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design of NNRTIs; they have also played an instrumental role in
understanding the mechanism of resistance.80
This section will discuss all three inhibitors, focusing mostly on NNRTIs.

(a) Nucleotide and Nucleoside Reverse Transcriptase Inhibitors (NtRTIs
and NRTIs). NtRTIs have one phosphate group, so they only require two
phosphorylation steps to become biologically active against HIV RT. They are
competitive inhibitors that bind to the RT active site and terminate chain
elongation. They have been shown to be very useful in patients with resistant
strains of HIV. For example tenofovir, also known as Viread showed a
reasonable reduction in HIV RT levels through week 96.64 Tenofovir is a prodrug
that requires deacylation prior to the phosphorylation steps.
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Azidothymidine (AZT) (Figure 2) was the first drug to be approved by the
FDA for AIDS therapy.4 It exhibited efficacy in lowering mortality rate and
reducing the frequency of opportunistic infection during an administration period
of 24 days. Further studies confirmed that prolonged therapy delayed disease
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progression and lowered viral load significantly. Although AZT caused severe
side effects such as bone marrow suppression, its therapeutic abilities were far
more valuable than its side effects. The approval of AZT changed HIV infection
from a definite death sentence to a chronic disease. Following AZT, 2′,3′dideoxycytidine (DDC) and 2′,3′-dideoxyinosine (DDI) were reported to have antiHIV activity. Both were effective in adults and children and were later approved
by the FDA; however, their approval came with restrictions. DDC was only to be
administered in combination with AZT, and DDI was only approved for patients
who have developed resistance or intolerance to AZT.82, 83 Another NRTI that
was FDA approved for anti-HIV therapy is 2′,3′-didehydro-2′,3′-dideoxythymidine
(D4T, stavudine, Zerit). In more recent years other NNRTIs have emerged to
play a key role in combination HIV therapy. Emtricitabine, 2′,3′-dideoxy-3′-thia-5fluorocytidine ( (-)-FTC) was approved by the FDA in July 2003. It has proved to
be one of the best HIV drug candidates on the market because it works
synergistically with a variety of anti-retrovirals, has a long cell half life, and
therefore can be administered once daily. It also has excellent bioavalability and
has 4–10-fold higher in vitro efficacy compared to other NRTIs.65 Figure 2 shows
structures of different NRTIs.

(b) Non-nucleoside Reverse Transcriptase Inhibitors. HEPT (1-[(2hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine) and TIBO (4,5,6,7tetrahydroimidazole[4,5,1-jk][1,4]benzodiazepine-2(1H)-one and –thione) are the
first two non-nucleoside reverse transcriptase inhibitors to be identified. They
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Figure 2. FDA approved nucleoside reverse transcriptase inhibitors
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exhibited specific activity against HIV-1, but not HIV-2, and they were identified
as reverse transcriptase inhibitors.84
HEPT was originally tested in 1987 for its activity against herpes simplex
virus (HSV). It was found to be inactive against HSV; however, it displayed
marked activity against HIV-1 RT. Following the original HEPT compound (TS-II25), other derivatives were synthesized such as E-BPU and E-EBU-dM. The
most significant HEPT derivative of all is MKC-442 (also known as I-EBU or
emivirine). It was designed using structure–activity relationship studies. In early
clinical studies, emivirine exhibited great bioavailability and no mitochondrial,
bone marrow or reproductive toxicity. It was moved quickly to phase II studies;
unfortunately, its development was discontinued.85 Further SAR studies led to the
development of more flexible HEPT derivatives such as TNK-6123. The major
change in TNK-6123 is the presence of a cyclohexylsulfonyl group on C6 as
opposed to a benzyl group. This was thought to give a larger range of motion for
the compound so it can adapt to mutated RT pockets. This proved to be true as
TNK-6123 showed 30-fold increase in activity as compared to MKC-442, and it
maintained activity against the K103N and Y181C mutants.37 Another set of
HEPT derivatives are the 2-alkoxy-6-benzyl-3,4-dihydro-4-oxopyrimidines
(DABOs) and 2-(cyclohexylsulfanyl)-3,4-dihydro-5-mehtyl-6-(3-methylbenzyl)-4oxopyrimidines (S-DABOs). A few of these compounds had comparable potency
against HIV-1 RT to that of MKC-442, but none superceded it. These
compounds are considered to be good candidates for microbicide use. Unlike
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their nucleoside reverse transcriptase counterparts, they do not just delay HIV
replication. They completely suppress it for up to 40 days.86
In 1989 TIBO derivatives were discovered through a national screening
program. TIBO’s discovery led to the characterization of the allosteric pocket in
which NNRTIs bind, now known as the non-nucleoside inhibitor binding pocket
(NNIBP).87 Interestingly, TIBO and HEPT were structurally different; however,
they shared some common features. Both had a bridge or body, and two
hydrophobic (either aromatic or aliphatic) “wings.” Crystallographic studies
proved that these compounds took on a butterfly-type conformation when bound
in NNIBP.88, 89 Following TIBO and HEPT, derivatives of other structurally
unrelated compounds were identified as NNRTIs. Three were approved by the
FDA, nevirapine (Verimune), delivaridine (Rescriptor) and efavirenz (Sustiva).85
NNRTIs have a unique specificity to HIV-1 RT regardless of the natural
substrates present in the active site. This suggests that these inhibitors make
contact within an enzyme site that is independent of the active site. They are also
very specific to HIV-1 RT, and display little to no activity against HIV-2 SIV or
cellular DNA polymerases α,β and γ. Chimeric enzymes of HIV-1/HIV-2 RT and
HIV-1/SIV RT have been reported. The exchange of certain amino acids in HIV2 and SIV with HIV-1 residues renders these RTs more sensitive to NNRTIs.90-94
This suggests that amino acids that are present in HIV-1 and not in HIV-2 or SIV
are important for NNRTI activity. Although this feature poses a challenge in
making NNRTIs that are active against both HIV-1 and HIV-2 RTs, it also
contributes to their low toxicity and high bioavailability.5, 95-101 It is worth noting
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that NNRTIs active against wt HIV-1 RT have also exhibited activity against
some mutant HIV-2 RT. The main difference between HIV-1 and HIV-2 RT is the
residues forming the allosteric binding pocket. In wt HIV-1 RT these are mainly
hydrophobic aromatic residues, while in wt HIV-2 RT they are primarily aliphatic
residues. In some mutant HIV-2 RT stratins, some residues mutate to aromatic
hydrophobic amino acids, which makes it easier for wt active NNRTIs to bind;
therefore, some activity is observed.102, 103 Figure 3 shows structures of relevant
NNRTIs.

F. The Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket
NNRTIs bind to an allosteric pocket located 10–15 Å away from the active
site that is related structurally and functionally to the active site (Figure 4). The
pocket lies in the p66 palm domain. It is mainly a hydrophobic pocket comprised
of the β-sheet (β4,β7,β8), more specifically amino acids 105–110, 179–191 and

β9,β10 and β11 amino acids 224–241, as well as residues 98–104 preceding β4
and residues 138,139,141 and 318. The roof of the pocket is lined by aromatic
residues Tyr181, Tyr188 and Trp229. The walls are lined with Leu100, Val106
and Leu234; the floor contains the Lys101–Lys103 domain. The putative
entrance of the NNIBP is thought to consist off Pro-95, Leu100, Lys101, Lys103,
Val179 and Tyr181.104 These residues are involved in an intricate hydrogenbond network that might act like a “gatekeeper” keeping inhibitors out. Inhibitors
that are successful in entering the pocket must be able to overcome the energy
barrier required to break these hydrogen bonds. Steered molecular dynamic
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studies suggest that this could be accomplished by inhibitor–residue hydrogen
bond formation or very strong hydrophobic interactions.104.
Pro225 and Pro236 form the mouth of the pocket which is thought to essentially
“close the door” after NNRTIs have entered.87, 105, 106 Glu139, Thr138 of p55 play
a structural role and lie left of the pocket.33, 38, 107, 108 In general a NNRTI causes
a conformational change in the β-sheet of p66 subunit locking the catalytic triad,
Asp110, Asp185, and Asp186, into an inactive conformation similar to that in the
noncatalytic p55 subunit, as well as locking the thumb subdomain into the
inactive upright position.105 The binding pocket does not exist in the unbound
RT. In the presence of a NNRTI dramatic conformational changes occur in the
pocket residues. The most noticeable change is the rotation of Tyr181 and
Tyr188 side chains upwards towards the catalytic triad and the β-sheet, formed
by β4,β7, and β8, shift ~2 Å.104 This results in a decrease in catalytic activity and
is considered to be the basis of NNRTI inhibition.5, 37, 87, 105, 109
Although structurally diverse, most NNRTIs adopt a butterfly conformation
when bound to HIV-1 RT.5 Schafer and co-workers were first to provide
evidence of such conformation.88 At the time no crystal structures of NNRTIs
bound to HIV RT were available; however, through conformational studies of
three inhibitor crystal structures, they found that all three inhibitors adopt a
rooftop-like conformation, or “butterfly conformation.” Later on, many other
NNRTIs were designed to fit this conformation.110-112 The major features needed
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Figure 4. The non-nucleoside reverse transcriptase inhibitor binding
pocket (NNIBP).
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for a compound to fit the butterfly conformation are (i) two π-systems, (ii) a body
or bridge that connects these two systems, usually with a thiocarbonyl, carbonyl,
or sulfonyl moiety, (iii) a methyl, or alkyl, group on the meta-position of the
extended π-system. The key feature that all these inhibitors share is the rigid
ring structure.88 In more flexible NNRTIs the butterfly conformation is less
obvious, or in some cases nonexistent.5
Each NNRTI differs slightly in its interaction with the binding pocket. The π–π
interactions with Tyr181, Tyr188, Trp229, and Tyr318 are the most important
interactions, followed by electrostatic interactions with Lys101,103 and Glu138.
With the exception of nevirapine, all NNRTIs form hydrogen bonds with at least
one of these residues. The van der Waals interactions with Leu100, Val106,
Val179, Tyr181, Cys190, Trp229, Leu234, and Tyr318 are also important in
stabilizing NNRTIs in the pocket.5
Hydrogen bonding has especially proved to be important for efavirenz in
maintaining its activity against the clinically relevant Y181C strain.113 Generally,
a hydrogen bond requires a distance less than 3.2 Å and an angle of 120º ± 30º.
The presence of a hydrogen bond adds ~2.5 kcal/mol to the binding energy,
further stabilizing the NNRTI/pocket complex.114

G. NNRTI-Induced Mutations
The first NNRTI-induced mutations discovered were the K103N
(Lys103Asn103) and Y181C (Tyr181Cys181) strains. These two mutations
rendered RT resistant to all NNRTIs. More specific mutations to individual
inhibitors have been observed as well, for example HEPT, derivatives induce
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K103N, V108I and Y181C mutations.115 Other mutations that are observed are
G190E, L100I, V106A, L74V, V75I, L100I, E138K, and P236L.84 Although
mutations make NNRTIs less attractive as therapeutic options, some of these
compounds such as MKC-442 and efavirenz maintain good activity against
mutant RT strains.84 Efavirenz maintains its activity levels in mutant strains
V108I, E179D, Y181C as in wt HIV-1 RT.116 Severe resistance to NNRTIs in
patients is only observed with double mutant strains; however, it is unclear how
quickly these double mutations arise in vivo in patients under NNRTI therapy.
Some of the most common double mutations are L100I/K103N, K101D/K103N,
and K103N/Y181C.84 Mutant RT’s resistance to NNRTIs varies from one inhibitor
to another. In other words, some mutations may cause little effect on one
inhibitor but render others completely inactive. Table 1 shows resistance
mutations that appear in patients taking NNRTIs as part of there HIV therapy.5
Each of these mutations elicit a different reaction from the three FDA-approved
NNRTIs. 5 Interestingly, RT’s resistance profile to NNRTIs differs completely from
resistance to NRTIs. All NNRTI mutations occur in the NNIBP pocket, while
NRTIs mutations occur all over the RT enzyme, and strains resistant to NNRTIs
maintain their activity against NRTIs and vice versa.5 This further stresses the
importance of combination therapy.

H. Sultams: A novel class of NNRITs
Gussion and co-workers based their molecular modeling study on a lowresolution (2.9 Å) crystal structure to generate an all-atom molecular model of th
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Table 1. Resistance mutations in patients treated with nevirapine(NEV),
deliviradine (DLV), and efavirenz (EFV).5
Amino Acid

NNRTI that may

Mutations

select for the
mutation

98-AlaGlu

NEV

100LeuIle

NEV, DLV,EFV

101-LysGlu

EFV

103-LysAsn/Thr

NEV,DLV,EFV

106-ValAla

NEV,DLV

108-ValIle

NEV,DLV

135-

EFV

IleMet/Thr/Leu
179-ValAsp/Glu

EFV

181-TyrCys/Ile

NEV,DLV,EFV

188-

Nev,DLV,EFV

TyrCys/His/Leu
190-

NEV,DLV,EFV

GlyGlu/Ala/Ser
225-ProHis

EFV

233-GluVal

DLV

236-ProLeu

DLV

238-LysThr

DLV
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NNIBP. A pocket was generated from the reverse transctriptase crystal Cα
coordinates.117
This was followed by docking experiments of nevirapine and a few other
analogues in order to identify elements of a pharmacaphore. Following the
identification of key functional groups in the pharmacaphore, a search on the NCI
database of over 200,000 compounds produced 300 hits. The search was then
modified to give 33 compounds including nevirapine and NSC119833 (Figure 5).
Further NCI database searches and 3D QSAR (quantitative structure–
activity relationship) studies paired with biological testing of the hit compounds
led to the identification of NSC-108406 (Figure 5) with an IC50 ± 0.3 µM.
Watanabe and co-workers were the first to report a synthetic route to sultam
family of which of NSC-108406 is a member.118 Further work in our labs
developed several synthetic routes to over 65 analogues of these sultams.(Work
unpublished).
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Figure 5. Structures of NSC119,833, nevirapine and NSC-108,406.
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Figure 6. General structure of sultams developed by the Baker group

Sultams are derivatives of isothiazoles with an aromatic ring fused at C4
and C5. The sultams developed in our lab have the general formula shown in
Figure 6 above. The numbering begins with the sulfur atom. Both rings A and C
are aromatic rings, while ring B is a heterocyclic ring. The nitrogen is either
secondary or tertiary depending on the nature of R1. R2 in the meta-position on
ring C varies in functionality. In some derivatives ring A was substituted at C6,
C7 or both. The general synthetic route to these sultams is outlined in Scheme 1
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1-2

The synthesis commences with the coupling of a substituted
benzenesulfonylchloride to a primary alkyl amine. Lithiation at the ortho-position
(termed ipso lithiation) is established using an alkyllithium reagent such as nbutyllithium. The lithiated species is then coupled to an aryl aldehyde (I-2), and
then cyclization is accomplished by using a protic acid to afford a racemic
mixture sultam I-4. The racemate was then separated with chiral HPLC, and the
enantiomers were submitted the NCI for anti-HIV studies.119
Synthesis of sultams with halogen substitution required a modification to
the original route. The use of alkyllithium reagents for coupling is not suitable
due to the presence of a halogen on ring A. Lithium–halogen exchange can
occur, which may lead to other side reactions and unwanted products. Halogensubsitituted o-aminobenzophenone (2-1) undergoes diazotization using HONO.
SO2 is then added in the presence of ionic copper to form the sulfonyl
functionality. Condensation of (2-2) leads to the cyclization of the isothiazole ring
(2-3). Hydrogenation of the imine functionality, followed by alkylation gives the
desired sultam (2-5) in a racemic mixture (Scheme 2).
To synthesize sultams with substitutions on ring C, yet another synthetic
route had to be devised (Scheme 3). 2,4-Dimethoxyphenyl-(4-methoxyphenyl)
methylamine is condensed with benzenesulfonylchloride. The product is lithiated
and coupled to an aryl aldehyde or ketone. The monoalkylated and dialkylated
compounds are isolated, and both are cyclized using a strong protic acid to give
the desired sultam.119
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N
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Another class of sultams is those with a CF3 group at C3. The synthetic route
leading to such compounds begins with the coupling of tert-butylamine with
benzenesulfonyl chloride (4-2). Alkylation of the resulting sulfonamide (4-3) is
afforded by treatment with sodium hydride and iodomethane. The resulting
product is then lithiated and coupled to an aryl ketone. Sulfuric acid catalyzed
cyclization produces the desired
Separation of these racemates was accomplished either by chiral HPLC
using a Chiralcel OD column or by derivitization of these compounds into their
diastereomers, then separation through chromatography and recrystallization.
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Biological studies of all of these compounds showed decreased activity
when the A ring was substituted. The preferred substitution on ring C was the

meta-position. In order to synthesize additional sultams with substituents on the
meta-position of ring C, another synthetic route was devised. In this route
saccharin was used to install rings A and B. It was coupled with an aryl Grignard
reagent to give 3-aryl-1,2-benzisothiazole 1,1-dioxide. The C=N imine bond was
then reduced enantioselectively to give enantiomerically pure products.
Methylation using Cs2CO3 and iodomethane gave the desired sultams (Scheme
5).
A report in C & E News suggested that rhodium can be used to give
racemic mixtures in various amine reductions.155 Using
pentamethylcyclopentadienyl as a ligand in place of the η6-arene ligands that
were traditionally used in such complexes,121 especially in the Noyori ruthenium
catalyst for C=O and C=N hydrogenations. Our laboratories designed and
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prepared a chiral Rh-Cp* complex. Pentamethylcylopentadienylrhodium chloride
dimer {[Cp*RhCl2]2} was coupled to (1R,2R)-N-p-toluenesulfonyl)-1,2diphenylethylenediamine {(1R,2R)-TSDPEN} to afford the R,R-catalyst and
(1S,2S)-TSDPEN was used to prepare the S,S-catalyst. Although the catalyst is
considered to possess three chiral centers, the metal and the two centers on the
TSDPEN ligand, it will be refered to as S,S when the S,S-ligand is used and R,R
when the R,R-ligand is employed. The structure of the R,R-catalyst was
confirmed with X-ray crystallography, and its activity was tested on a variety of
compounds. Although the resulting enantioslectivity is modest, simple
recrystallization methods of these enantio-enriched mixtures afforded the pure
enantiomers. Polar solvents were preferred; however, dichloromethane was just
as efficient and the enantioselctivity was not affected. The most suitable proton
source was found to be formic acid/triethylamine azeotrope. Reactions failed
when 2-propanol/triethylamine was used. The substrate-to-catalyst ratio (S/C) is
200:1, while the Noyori catalyst requires a ratio of 100:1. Reactions times were
short, and yields were very good. The enantioselectivity of this catalyst proved to
be interesting. Generally, the S,S-catalyst produced the R product and vice
versa; however, this observation is greatly affected by the nature of the
substrate. The bulkier groups such as the sultams with an aromatic C ring
followed this phenomenon, and the smaller compounds such as sultams with
alkyl groups in place of ring C gave the opposite results.122 It is worth noting that
this catalyst exhibited very good stability, and was not hygroscopic or sensitive to
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air as many similar complexes are. It also remained active at low temperatures,
and higher temperatures did not seem to affect its enantioselectivity or activity.
With the short synthetic route using saccharin, and the enantioselective
catalyst at hand, we have designed and prepared new sultams with potential
anti-HIV activity.
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II. Statement of the Problem
AIDS is currently the largest worldwide epidemic known in this century. In
an effort to join the many medicinal chemists in their battle against AIDS, we plan
to use computer-aided docking experiments to design new sultams that will be
active against wild-type reverse transcriptase (wt RT), as well as mutant RT, in
particular the Y181C RT strain. Using RT crystal structure coordinates, the target
sultams will be docked into the allosteric pocket of RT, and flexible docking
(FlexiDock) experiments performed, using genetic algorithms to find the lowest
energy conformation. The results will be analyzed for distances between the
ligand and key residues and hydrogen bonding sites. While the calculated
energies produced by FlexiDock in the SYBYL program are not real, they will
serve as relative references to compare different fits. A synthetic route will then
be designed leading to the synthesis of these compounds. From the modeling
studies a set of compounds based on our 2,3-dihydro-3-(m-methylphenyl)-1,2benzisothiazole 1,1-dioxide and Merck’s efavirenz will be examined. The best
candidates structures will then be synthesized for evaluation.
In the course of this work, we will collaborate with Professor John Turner
and his student Megan Bragg on some NMR studies of the rhodium catalyst to
identify the catalytic cycle. While Turner and co-workers will study the catalytic
cycle through variable-temperature NMR studies, as well as some 2D
experiments, we will attempt to further support their findings through molecular
modeling studies. The same principles of docking a substrate into an enzyme
will be used. Various sultams will be docked into the catalyst. The complex will
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then be minimized and analysis of bond lengths and angles used to predict
interactions.
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III. Results and Discussion
A. Modeling
1. The Tripos Force Field
The four major components in the energy expression of the Tripos force field are
the following:123-125
(a) Stretching energy expression: the energy of a bond stretched or
compressed from its original bond length.
Estr =

ΣE

str (1/2)ki

d

(di−di0)2

di = the length of the ith bond (Å)
di0 = equilibrium length of the ith bond (Å)
kid = Bond stretching of force constant (kcal/(mol)(Å)2)
(b) Angle-bending energy term: the energy from bending bond angles out
of their natural values.
Ebend =

ΣE

bend (1/2)

kiθ(θi−θi0)2

θI = angle between two adjacent bonds
θi0 = the equilibrium value of the θ
kiθ = angle force constant (kcal/(mol)(º)2)
(c) Out-of-plane bending energy term: energy of bending planar atoms out
of their plane.
Eoop=

ΣE

oop
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(1/2)kioop di2

di = distance between the center atom and the plane of its substituents.
Kioop = the force constant for out of plane bending (kcal/(mol)(º)2
(d) Torsional energy term: energy due to twisting around bonds.
Etors = (1/2) Viω[1+Sicos(|ni|⋅ωi)]
Viω= Torsional barrier (kcal/mol)
Si = +1 minimum energy when staggered, −1 minimum energy when
eclipsed
ni = Periodicity

ωI = torsion angle
(e) van der Waals energy term: energy resulting from van der Waals
interactions.
Evdw =

Σ Σ
i=1

i>j

[

]

Eij (1.0/aij12)-(2.0/aij6)

Eij = van der Waals energy constant (kcal/mol)= (EiEj)1/2
aij = rij /(Ri + Rj)
rij = distance between atoms i and j (Å)
Ri = van der waals radius for the atom I (Å)
The Tripos energy expression also contains optional terms such as energy
from electrostatic interactions and energies from distant, angle and torsional
constraints as well as a multifit energy term associated with multifits. These
expressions are only used when information about them is specified. In the
FlexiDock modeling studies described here and in the simple minimizations done
on the sultams, no constraints were defined prior to the calculations; therefore,
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these energy terms were not used in these calculations. However, distance and
angle constraints were used in the rhodium catalyst molecular modeling studies
so some of these terms were automatically incorporated into the calculations. It
is important to keep in mind that any energy produced by a force field is not real,
meaning it holds no physical value for individual conformations. Energy values
are used as points of reference to compare different conformations for a given
molecule as well as difference among a set of similar molecules.
The Tripos force field was used in its default parameters for all
inhibitor/protein docking experiments. For the rhodium catalyst calculations
parameters for the rhodium metal center were added from the SYBYL metal
database provided to all users.
2. Charges
All small-molecule charges were calculated using the Gasteiger-Hückel
method, which is a combination of two calculations. The π charge is assumed to
be delocalized on all π atoms and calculated first using the Hückel method,126
and then the σ charge is calculated using methodology outlined by Gasteiger and
Marsili.127, 128
All protein charges were calculated using the Pullman and Berthod
method, which is a combination of two methods, the Del Re method for σ charge
calculation and the Hückel method for the π charge calculation.129, 130
3. FlexiDock
FlexiDock is a docking program that utilizes crystal structure coordinates
of known protein/inhibitor complexes. The protein atoms are fixed coordinates in
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space, while the ligand is mobile, i.e., rotation and translation of the ligand in
space can be applied. The protein residue side chains can be designated as
flexible. To achieve faster calculation times, only single non-ring bonds and
amide bonds were allowed to flex (rotate). FlexiDock uses the Tripos force field
(ff) to calculate energies of the different conformations generated by the genetic
algorithm. The default parameters between the two force fields are essentially
the same; however, a few differences are present and they are summarized in
Table 2 below.
FlexiDock uses a steady-state genetic algorithm to generate, propagate
and reproduce these genes. Genetic algorithms are global optimizers that
employ terminology and methodology from Mendelevian hereditary practices and
Darwinian evolutionary theories in which the most fit members of a population
are allowed to propagate into future generations.

Table 2. Default Settings in FlexiDock and Tripos Force Field (from
SYBYL FlexiDock Manual).
Default Condition
Hydrogen van der Waals
radius
Hydrogen van der Waals
Є
van der Waals distance
cut off

FlexiDock
1.0 Å

Tripos Force Field
1.5 Å

0.03

0.042

16.5 Å

8.0 Å
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The algorithm begins with the formation of the initial population of
chromosomes. A chromosome is a set of possible torsional, translational, and
rotational positions a flexible bond might have. The number of genes on each
chromosome depends on the number of rotatable bonds specified. The
chromosomes are then evaluated for energy using the the Tripos ff. The best fit
members of a population are then allowed to mutate or cross over. The new
generation is then evaluated again for energy values and so on and so forth.131
The purpose of FlexiDock calculations is to explore the diverse solution space
available for a specific problem. FlexiDock monitors this diversity by monitoring
the percent of gene convergence. When 95% of the genes have converged, the
calculation terminates, and the best twenty solutions are placed in a molecular
database. The number of generations used in a FlexiDock run depends on the
number of flexible bonds designated by the user. A more flexible ligand/protein
complex requires a larger number of generations. It is agreed that a minimum of
500 to 1000 generations per gene are required to produce reasonable results.131
A gene is the total number of flexible bonds in the ligand and the protein plus six.
The default setting for FlexiDock is 3000 generations. This value assumes there
are no flexible bonds in the ligand or protein; therefore:
(0 + 6) (500)= 3000
In the FlexiDock experiments reported here the average number of bonds
being flexed in both protein and ligand were around 50 bonds. This means a
minimum of 28,000–56,000 generations are needed to produce some results.
This of course is a minimum value and a higher number of generations is
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acceptable. To allow a larger solution set to be discovered the maximum number
generations was 130,000. Each complex was minimized at least three times at
varying seed numbers. This allows FlexiDock to explore a wider range in the
solution space. Each run gave 20 solutions, and all 60 solutions for each of
these runs were evaluated quantitatively and qualitatively. A hydrogen-bond site
was not specified in these studies. Distances and angles between potential
hydrogen donors and acceptors were evaluated.114 Based on these results,
hydrogen bonding was predicted between the ligand and certain residues in the
pocket.
4. Preparing the Protein
Two major FlexiDock studies were prepared using wt RT and Y181C RT bound

to efavirenz (pdb code 1ikw, 1jkh).132, 133 The crystal structures were obtained from the
protein databases. Efavirenz was extracted and deleted from the crystal structure.
Hydrogens were added at random orientations, and Pullman charges were calculated for
each protein. A minimization was performed where the protein is treated as an aggregate
or rigid structure and the hydrogens are considered flexible. This was necessary to
optimize the position of the added hydrogens. Minimizations on the protein crystal
structures were attempted; however, these studies did not yield any major differences in
the orientation of the protein backbone.
5. Defining the pocket
The non-nucleoside inhibitor binding pocket (NNIBP) was defined based
on available biochemical and molecular modeling data.31, 88, 108, 109, 134-136
Hydrophobic interactions require a distance between the ligand and the residue
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of 4 Å.114 Weaker binding interactions do occur at distances larger than 5 Å;
however, any residue that is more than 10 Å away is not considered for binding.
Such residues may be important for binding pocket formation or structural
stabilization but not direct ligand–residue interactions. The pocket was defined as
a sphere with a radius of 10 Å and the inhibitor at its center. Manual inspection
of the residues included in this sphere showed that all the key residues that form
the NNIBP are present (see The non-nucleoside reverse transcriptase binding
pocket section in the Introduction).
6. Preparing the sultams
All sultams were sketched using the Sketch Molecule menu in SYBYL.
Hydrogens were then added and Gasteiger–Hückel charges were calculated. A
quick minimization was then employed to minimize the adjust bond lengths and
angles that may have been distorted during the sketching process.
7. Docking the sultams
In docking experiments it is very helpful to have a starting position that the
inhibitor can be placed in. Efavirenz coordinates in the crystal structure were
used to position the sultam inhibitor. The sultam was superimposed on top of
efavirenz while it was still in the pocket and a three-atom fit was performed.
Efavirenz was then deleted from the sequence, and the sultam merged into the
enzyme. This technique provides a better pre-positioning of the inhibitor and
eliminates the cumbersome process of manually docking inhibitors into the
pocket. RMS values for the sultam/efavirens fit are reported in Table 3.
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Table 3. RMS values for sultam/efavirenz fit

Sultam

RMS

3-(Cyclopropylethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
3-(Cyclobutyethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
3-(tert-Butylethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
3,3-Bis(cyclopropylethynyl)-2,3dihydro-2-methyl-1,2-benzisothiazole
1,1-dioxide
3,3-Bis(cyclbutylethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
3,3-(di-tert-Butylethynyl)-2,3-dihydro 2methy 1,1-dioxide
3-(Cyclopropylethyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide
3-(Cyclobutylethyl)-2,3-dihydro-2methyl-1,2-benzisohtiazole 1,1-dioxide

0.36
0.32
0.29
0.32

0.32
0.32
0.39
0.31

8. Preparing the FlexiDock File
The FlexiDock file is prepared by following a checklist provided by the
FlexiDock menu:
(a) Define pocket: The pocket is defined as the NNIBP previously
specified plus 1 Å around it.
(b) Extract ligand: Ligand is extracted and deleted from the protein
sequence. This is done to allow each of these structures to be
prepared separately.
(c) Remove water molecules: FlexiDock removes all water molecules that
belong to the set {WATER}. These water molecules were generated
when the pdb files were read in from the protein database.
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(d) Check atom types: This provides an option to modify any atom types
that may have been improperly downloaded from the pdb file. This
was particularly common in previous SYBYL versions; however, the
current version SYBYL7.2 has less of a problem.
(e) Add hydrogens: Since hydrogens were previously added on both the
protein and ligand, no more hydrogens were added at this stage.
(f) Add charges: the charges for the protein and the sultam have been
individually calculated so the charges do not need to be reloaded again
(g) Rotatable bonds: For the 3-(alkylethynyl)-2,3-dihydro-2-methyl-1,2benzisotiazole 1,1-dioxide (alkylethynyl sultam series), the N-methyl
bond was allowed to rotate. Flexible Residues: Lys101, Lys103,
Tyr181or Cys181 (for Y181C mutant strain), Tyr183, Tyr188 (Cys188
for Y188C), Trp229, Tyr318 were all chosen to have flexible side
chains. (See below for a discussion on the reasoning behind choosing
these ligands).
(h) Specify hydrogen-bond sites: No hydrogen-bonding sites were prespecified in these studies. The ligands were allowed to flex in the
pocket without any H–bond constraints. Then using distances and
angles between the ligands and hydrogen-bonding residues, we
predicted the presence of a hydrogen bond.
(i) Pre-position ligand in the pocket: Since the sultam was fitted to the
efavirenz coordinates in the RT pocket, it was not necessary to alter
the ligand’s position any further.
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(j) Name file: Create a name for the FlexiDock File
(k) Write output file: this creates the FlexiDock file with the name specified
in the previous step
(l) FlexiDock it: this begins the flexidock calculation.
Once the FlexiDock run is started, a random seed number is generated.
All random seed numbers were noted. As mentioned earlier the number of
generations used was 130,000 generations in each of the runs. Once FlexiDock
was done, a set of twenty solutions are placed in a molecular database along
with their energies.
9. FlexiDock Studies
The residues chosen for flexing are mentioned above. Each of these
residues plays a key role in inhibitor binding. Lys101 forms hydrogen bonds with
wt RT. Lys103 is part of the lysine triad Lys101–Lys103 (wing 1) and its
orientation positions Lys101 for hydrogen bonding with the bound inhibitor. It is
also involved in pocket formation. In the Lys103Asp103 (K103N) mutant strain
efavirenz looses a good percentage of its activity because Lys101’s orientation is
distorted and no hydrogen bond is formed.137, 138 Tyr181, Tyr188 and Trp229
form the hydrophobic region of the pocket also known as the wing 2 region.5, 85,
104

A number of π–π hydrophobic interactions form the basis of NNRTI binding to

RT. Most inhibitors rely on the three main aromatic ring-stacking interactions;
parallel (strong), staggered (medium) and T-shaped interactions (weak).
Tyr181Cys181 is the most frequently occurring mutation observed in
HIV patients receiving NNRTIs as part of their regimen. Trp229 is the only
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conserved amino acid across all HIV-1 reverse transcriptase strains in wt RT as
well as Y181C RT. Tyr318 is part of the wing 1 region, which is mostly
comprised of non-aromatic residues such as the lysine triad. Analysis of the
observed distances between efavirenz and Tyr318 in wt RT and Y181C RT
suggests that this residue increases in importance as wing 1 loses some of its
hydrophobic character in Y181C.
In order to keep calculation times within reason, the aforementioned
residues were chosen to be the focus of the docking experiments. The NNRTI
binding pocket formation and binding process is a flexible and complex process.
As these residues open up to form the binding pocket, they cause both local and
global movement in the enzyme leading to inhibition of activity. The FlexiDock
studies reported here are localized studies and do not take into consideration the
global effects on the overall protein conformation. The sultams shown in Figure
7 are considered to be structurally related to efavirenz. Analyses of the docking
results were done in comparison to efavirenz and its position in the NNIBP
pocket. Table 4 reports the distances and hydrogen-bond angles for efavirenz in
(a) wt and in (b) Y181C RT.
In binding studies a hydrophobic interaction is considered strong if the
distance between the ligand and residue is less than 4 Å. A distance between 4
and 5 Å is thought to cause a moderate binding interactions, and anything larger
than 5 Å is classified as a weak binding interaction.114 The FlexiDock cut off for
van der Waals interaction is 16.5 Å; however, any distance greater than 10 Å will
be considered negligible.
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Figure 7. Structures of the alkylethynyl sultam series.
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Table 4. (a) Distances and H-bond angle in the efavirenz/wt RT complex. (b)
Distances and H-bond angle in the efavirenz/Y181C RT complex
a.

Efavirenz

Residue in wt RT

Distance

Angle of H-bond if

(Å)

present (º)
98.55º

C=O

Lys101

2.06

Cyclopropyl

Tyr181

2.544

Tyr183

7.23

Tyr188

5.96

Trp229

4.49

Aromatic ring

Tyr318

5.84

Efavirenz

Residue in Y181C

Distance

Angle of H-bond if

RT

(Å)

present (º)

C=O

Lys101

2.31

97.76

Cyclopropyl

Cys181

—

Tyr183

7.26

Tyr188

3.99

Trp229

4.04

Tyr318

5.00

b.

Aromatic ring
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Efavirenz forms a hydrogen bond in both the wt and Y181C RT with
distances between the amide carbonyl in efavirenz and Lys101 at 2.06 Å and
2.31 Å for wt and Y181C, respectively, with angles of around 98º for both. Both
angle and distance values are within what is needed for hydrogen bonding to
occur in biological systems.114 Efavirenz is known to cause selection for Y181C
mutation. This is greatly supported by the significantly small distance, 2.54 Å,
between the cyclopropyl group and Tyr181 in wt RT. In wt RT the cyclopropyl
ring is almost 6 Å away from the Tyr188, but this distance is decreased by 2 Å in
Y181C.
This occurs to compensate for the loss of the major hydrophobic
interaction at Tyr181Cys181. It is also worth noting that the cyclopropyl group
becomes almost equidistant from both Tyr188 and Trp229 at 4 Å. The aromatic
ring in efavirenz is 6 Å away from Tyr318, and it is positioned in a T-shaped
orientation towards the ring. It could be hypothesized that the weakest type of π–

π interaction, the T-shaped interaction, is occurring here. In Y181C the aromatic
ring is closer to Tyr318 by 0.8 Å; however, its orientation does not change. Figure
8 shows the positions of efavirenz in both wt RT and Y181C Rt.
Tables 5–7 display the distances and hydrogen-bond angles (when
hydrogen bonding is present) calculated by FlexiDock for 2-(alkylethynyl)-2,3dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide (the alkyethynyl sultam series,
compounds 9–11). The Flexidock calculations predict a hydrogen bond between
the sulfonyl group of cyclopropylethynyl sultam (9) and Lys101. The distance
observed after calculations is 2.10 Å and an angle of 115º.
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K103
Y318

K101

K103

Y318

Y188
W229

C181

Y181

W229

Y188
Y183
Y183

Figure 8. Efavirenz in wt RT (left) and Y181C (right).
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Table 5. (a) Flexidock distances for cyclopropylethynyl sultam (9); (a) wt RT; (b)
Y181C RT
5a.

Cyclopropylethynyl
sultam

Residue in wt RT

SO2
Cyclopropyl

Distance

Angle of H-bond if

(Å)

present (º)

Lys101

2.10

115

Tyr181

4.20

Tyr183

7.85

Tyr188

5.6

Trp229

4.54

Tyr318

6.11

Cyclopropylethynyl
sultam

Residue in Y181C

Distance

Angle of H-bond if

(Å)

present (º)

SO2

Lys101

2.19

119.06

Cyclopropyl

Cys181

—

Tyr183

7.86

Tyr188

4.32

Trp229

5.24

Tyr318

4.86

Aromatic ring

5b.

Aromatic ring
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Table 6. FlexiDock results for tert-butylethynyl sultam (10) in (a) wt RT, (b)
Y181C.
6a.

tert-Butylethynyl

Residue in wt RT

sultam

Distance

Angle of H-bond if

(Å)

present (º)
—

SO2

Lys101

3.00

tert-Butyl

Tyr181

5.09

Tyr183

7.88

Tyr188

4.3

Trp229

4.55

Tyr318

4.91

tertButylethynylsultam

Residue in Y181C

Distance

Angle of H-bond if

(Å)

present (º)

SO2

Lys101

2.13

127

tert-Butyl

Cys181

–

Tyr183

7.19

Tyr188

4.19

Trp229

4.75

Tyr318

4.74

Aromatic ring

6b.

Aromatic ring
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Table 7. FlexiDock results for cyclobutylethynyl sultam (11) in (a) wt RT and (b)
Y181C RT.
7a.

Cyclobutylethynyl
sultam

Residue in wt RT

SO2
Cyclobutyl

Distance

Angle of H-bond if

(Å)

present (º)

Lys101

4.27

—

Tyr181

4.61

Tyr183

7.54

Tyr188

4.60

Trp229

4.01

Tyr318

5.95

Cyclobutylethynyl
sultam

Residue in Y181C

Distance

Angle of H-bond if

(Å)

present (º)

SO2

Lys101

2.31

124

Cyclobutyl

Cys81

—

Tyr183

7.70

Tyr188

4.41

Trp229

4.87

Tyr318

4.85

Aromatic ring
7b.

Aromatic ring
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For the tert-butylethynyl sultam (10), no hydrogen bond is predicted. The
distance observed is 3 Å,. According to Mager and co-workers distances greater
than 2 Å greatly weaken hydrogen bonding.114 It is difficult to definitively
conclude whether the tert-butylethynyl sultam (10) forms a hydrogen bond with
Lys101. The cyclobutylethynyl sultam (11) is 4.27 Å away from Lys101. A large
distance such as this one suggests that no hydrogen bond is formed. In wt RT
all three alkyl groups (cyclopropyl (9), tert-butyl (10), and cyclobutyl (11)) are
between 4 Å and 5 Å away from Tyr181 which is at least 2 Å greater than the
distance observed for efavirenz in the pocket. The distances from Tyr188 vary
from one sultam to the other. The cyclopropylethynyl sultam (9) has the largest
distance of all three inhibitors at 5.6 Å, while tert-butylethynyl sultam (10) and
cyclobutylethynyl sultam (11) have similar distances ranging from 4.3–4.6 Å ,
suggesting hydrophobic interactions with this particular residue for both
inhibitors. All three inhibitors show a smaller distance between their alkyl groups
and Tyr188 than that observed in the efavirenz/wt RT crystal structure. All three
inhibitors are more than 5 Å away from Tyr183, which is a result similar to that
observed in the efavirenz/wt RT complex. For the conserved Trp229
cyclopropylethynyl- (9) and tert-butylethynyl (10) sultams are positioned at 4.5 Å
from this residue. Efavirenz is also around 4.5 Å.
Perhaps the most important observation for all three inhibitors in wt RT is
that none of them favor a hydrophobic residue as is observed in the efavirenz
pocket. It would be interesting to see whether or not these molecules induce
aspecific mutation in wt RT much like efavirenz. A visual inspection of aromatic
71

ring A finds all three inhibitors in a staggered orientation with Tyr318 and the
distance calculated for all three is around 6 Å. This could be a staggered π–π
weak interaction, but it is very hard to determine that. Figure 9 depicts all three
alktylethynyl sultam in wt RT superimposed over efavirenz. Figure 10 shows
each docked in the pocket separately. The white ligand in both figures is
efavirenz. Cyclopropylethynyl is red, ter-butylethynyl is blue and cyclbutylethynyl
is green. Hydrogen bonds are depicted with red or yellow dashed lines.

Figure 9. All alkyethynyl sultams docked into wt RT and superimposed on the
Efavirenz wt RT pocket. Red (cyclopropylethynyl), blue (tert-butylethynyl), green
(cyclobutylethynyl), white (efavirenz). The yellow dotted line H-bond between
Lys101 and cyclopropylethynyl sultam and red dotted line represents a hydrogen
bond between Lys101 and efavirenz..
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Y318

L101

Y181

W229

Y183

Figure 10. The alkylethynyl sultam series shown with efavirenz in wt RT and
Y181C RT.
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A noticeable change is that all three sultams lie closer to Lys101, and a
hydrogen bond is predicted to form for all three of them. The most dramatic
decrease in distance between the SO2 group and the Lys101 NH hydrogen is
observed in the cyclobutylehthynyl sultam where a decrease of 1.86 Å is
reported. The calculated distances between SO2 and NH Lys101 range
between 2.13 Å and 2.31 Å, and the observed H-bond length in efavirenz Y181C
crystal structure is 2.31 Å. Two sultams have shorter hydrogen-bond lengths
than those observed in the crystal structure of the efavirenz/Y181C RT complex.
The angles for these bonds range between 119º and 127º. All angles are within
the range observed for hydrogen bonding in biological systems (Figure 11).114
Visually these sultams appear to bind more similarly to efavirenz in this mutant
pocket than in the wt pocket. Refer to Figures 11 and 12 for images of the
docked sultams in Y181C superimposed on the efavirenz pocket.
Due to some synthetic challenges, of the three molecules discussed
above, we were only able to synthesize 3-(tert-butylethynyl)-2,3-dihydro-2methyl-1,2-benzisothiazole 1,1-dioxide (10) as a racemic mixture. However, five
other compounds that were produced as side products or unexpected products
were isolated. The 3-(cycloalkyl)-2,3-dihydro-2-methyl 1,2 benzisothiazole 1,1dioxides (cycloalkylethyl sultams, compounds 12 and 13) and the 3,3-(dialkyl)2,3-dihydro-2-methyl-12-benzisothiazole 1,1-dioxide (dialkylated sultams,
compounds 15, 16 and 17). Although these two groups of compounds were not
part of the original work, they made interesting candidates for docking
experiments.
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A

B

Figure 11. (A) 3-(cycloalkyethynyl) sultam in Y181C RT/efavirenz pocket.
(B) 3-(cycloalkylethynyl) sultam in pocket. Residues not shown
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A

B

L101

C

Y318
L103

C181
Y188
W229

Y183

Figure 12. (A) cyclopropylethynyl sultam in Y181C RT, (B) tert-butylethynyl
sultam in Y181C RT, (C) cyclobutylethynyl sultam in Y181C RT.
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Both 3-(cycloalkylethyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxides (12 and 13) were docked into wt RT and Y181C following the same
protocol outlined earlier with at least three separte experiments at different
random seed numbers and 130,000 generations. Each study gave twenty
possible solutions. The lowest energy conformation was then evaluated for
distances, hydrogen-bond lengths and hydrogen-bond angles. In the wt RT both
cycloalkylethyl sultams produced flipped conformations (Figure 13). Both the
cyclopropyl and cyclopbutyl groups are in the wing 1 region. Figure 14 shows
these two sultams superimposed with the efavirenz pocket without any amino
acid residues. It is also important to note the orientation of the ethyl group which
appears to be extremely strained. To quantitatively get a grasp on the energy of
these conformations, the lowest energies of both studies were compared to the
lowest energies from the Y181C docking studies. For 12, the lowest energy in
the wt RT pocket shown above is −260 kcal/mol while the lowest energy for the
Y181C pocket is −219 kcal/mol (41 kcal/mol decrease in energy). In the Y181C
the binding conformation of this sultam is similar to that observed in the efavirenz
pocket. It is important to stress that these energies have no real physical value
but serve as a point of reference in comparing the different binding
conformations. It is necessary here to rely on the energy values rather than the
distances and angles because these two conformations are completely different,
and their groups do not lie in the same regions of the pocket
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Figure 13. 3-(Cycloalkyethynyl) sultam in wt RT
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as efavirenz. For the cyclobutylethyl sultam 13, the lowest energy conformation
observed in wt RT is −244 kcal/mol, while it is −212 kcal/mol for Y181C ( 32
kcal/mol energy change). Again the binding conformation of the cyclobutylethyl
sultam 13 in Y181C mimicks that of efavirenz in Y181C and wt RT. Tables 8 and
9 report distanced and angles observed for both sultams. Figure 14 depicts them
in the Y181C RT cavity superimposed onto the efavirenz/Y181C RT crystal
structure.
Both inhibitors are predicted to form hydrogen bonds with Lys101. The
calculated distance between the sulfonyl group and NH of Lys101 is 1.77 Å and
1.74 Å for cyclopropylethyl sultam (12) and cyclobutylethyl sutlam (13),
respectively, (2.3 Å for efavirenz) with angles of 130.69º and 131.69º (Tables 8
and 9). Both inhibitors have distances that are no more than 5 Å away from
Tyr188,Tyr183, and Trp229. The cyclopropyl and cylobutyl rings are closest to
Tyr188 with a distance of approximately 4.10 Å for both. The binding
conformations of both inhibitors are very similar to that of efavirenz in the pocket
(Figure 14). Of all the inhibitors docked so far, these compounds make the most
interesting candidates for biological evaluation. The energies of these two
inhibitors in this particular pocket are significanlty lower than the calculated
energies of the other sultams discussed above. The alkylethynyl sultam series
lowest binding energies range between −260.01 kcal/mol and −269.65 kcal/mol,
while the lowest binding energies for the cycloalkylethyl sultam series are less
than −220 kcal/mol. Table 10 lists the lowest binding energies in both wt RT and
Y181C.
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Table 8. Distances and hydrogen-bond angles between cyclopropylethyl
sultam and key resideus in Y181C RT.
Cyclopropylethyl
sultam

Residues in
Y181C

Distance

Angle of H-bond if

(Å)

present (º)

SO2

Lys101

1.77

130.69

Cyclopropyl

Cys81

—

Tyr183

7.74

Tyr188

4.10

Trp229

4.66

Tyr318

4.80

Aromatic ring

Table 9. Distances and hydrogen-bond angles between cyclobutylethyl sutlam
and key residues in Y181C RT.
Cyclobutyllethyl
sultam

Residues in
Y181C

Distance

Angle of H-bond if

(Å)

present (º)

SO2

Lys101

1.74

131.69

Cyclobutyl

Cys81

—

Tyr183

7.49

Tyr188

4.09

Trp229

4.51

Tyr318

4.75

Aromatic ring
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A

B

Figure 14. (A) Cyclopropylethyl sultam (magenta) and cyclobutylethyl sultam
(yellow) in Y181C RT with efavirenz (white). (B) All three inhibitors in the pocket
with no residues shown.
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Table 10. . Calculted energies in both wt RT and Y181C RT

Inhibitor

Cyclopropylethynyl
sultam (9)
Cyclobutylethynyl
sutlam (11)
tert-Butylethynyl
sultam (10)
Cyclpropylethyl
sultam (12)
Cyclobutylethyl
sultam (13)

wt RT
Calculated
Energy
(kcal/mol)
−282.73

Y181 C RT
Calculated
Energy
(kcal/mol
−269.65

−284.04

−269.29

−276.10

−260.01

−260.00

−219.00

−240.00

−212.00
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The isolation of 3,3-bis(allylethynyl)-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxides (bisalkylated sultams compounds 15–17) as side
products from our reactions (see synthetic discussion section) prompted docking
experiments into wt RT and Y181C. The three compounds proved to be too
large for the wt RT. The docking experiments were tried several times, and the
lowest binding conformation was either placed outside of the pocket or in
conformations that made no contacts with the key residues being inspected. As
mentioned earlier, although NNRTIs are strucurally diverse, they all make key
contacts with specific pocket residues. These contacts were not observed in
these studies.
Compounds 15–17 were docked into Y181C RT using the
efavirenz/Y181C RT crystal coordinates. The binding conformations of all three
compounds did not adopt a similar orientation to that off efavirenz. However,
bis(cyclopropylethynyl) sultam (17) and bis(tert-butylethynyl ) sultam (16)
exhibited interesting binding interactions with certain pocket residues. Tables 11
and 12 report the calculated distances. The sulfonyl group for
bis(cylopropylethynyl) sultam (17) is no longer oritented toward Lys101, but
instead points directly at the SH moeity of Cys181. The distance measured is
3.96 Å. The bis-tert-butylethynyl (18) sultam has its SO2 group also oriented in a
similar fashion with a shorter distance of 2.37 Å. SYBYL does not predict a
hydrogen bond between the ligand SO2 and Cys181; however, these docking
experiments were performed at least three times, and sixty possible solutions
were inspected. The SO2 position was always reoriented towards Cys181. This
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Table 11. Distances between dicyclopropylethynyl sultam and key
residues in Y181C RT
Ligand

Residue

Distance (Å)

SO2

Cys181

3.96

Cyclopropyl (A)

Tyr183

5.72

Tyr188

5.77

Trp229

4.3

Tyr318

3.75

Cyclopropyl (B)

Table 12. Distances between the dyclopropylethynyl sultam and key residues in
Y181C.
Ligand

Residue

Distance (Å)

SO2

Cys181

2.37

tert-butyl (A)

Tyr183

7.32

Tyr188

5.006

Trp229

4.42

Tyr318

3.26

tert--butyl (B)

84

indicates that some sort of electrostatic interaction is ocurring, most probably a
hydrogen bond. The second most noticeable interaction is the position of one of
the cyclopropyl groups and tert-butyl groups. Both are oriented directly toward
the aromatic ring of Tyr318 and the calculated distances are 3.75 Å and 3.26 for
cyclopropyl (15) and tert-butyl (16), respectively. Tyr183 remains at least 5 Å
away from each ligand. Trp229 seems to also make contact with one cyclopropyl
group and one tert-butyl group at a distance less than 4.5 Å. Whether these
distances lead to binding and activity cannot be concluded from these results.
Since these compounds do not adopt a similar orientation to efavirenz in this
pocket, it is difficult to compare the observed crystal structure distances and the
calculated distances of our compounds. And it is also difficult to predict acitivity.
However, upon comparison of these structures with the nevirapine/Y181C RT
crystal structure, it was discovered that these bisalkylated sultams have similar
binding conformations to that of nevirapine (Figure 15). Nevirapine has very low
activity against mutant RT strains, particularly those with mutations in the
hydrophobic region such as Y181C and Y188C.85
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A

B

Figure 15. Dialkylated sultam 15 and 16 in Y181C/nevirapine pocket. (A)
Dicyclopropyl (violet), di-tert-butyl (red) nevirapine (white) with all residues. (B)
All three inhibitors without residues.
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B. Synthesis
1. 3-(Alkylethynyl)-1,2-benzisothiazole 1,1-dioxide
The original synthetic route leading to the ethynyl series followed a similar
plan developed by Baker et al. to synthesize 3-(R)-aryl-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1-dioxides (Scheme 5 ).119 Two equivalents of aryl magnesium
chloride or bromide Grignard reagents were coupled with one equivalent of
saccharin to give the respective 3-(aryl)-1,2-benzisothizole 1,1-dioxides in good
yield.119 Following the same logic, a synthetic route was outlined using
alkynylithium reagents with saccharin to give the desired 3-(alkylethynyl)-1,2benzisothizole 1,1-dioxides using methodology developed by Abromovitch et al.
(Scheme 3).139
Scheme 6
O O
S
NH

2 R

O
O
S
N

Li

THF/ -78 oC-r.t.

O

(R,R)-[TSDPEN]RhCp*
S/C 200:1, HCOOH:Et3 N (5:2)
r.t.

R
O
O
S
NH
H
R

O
O
S
N Me

1.1.5 equiv Cs2CO3 /DMF or CH 3CN/r.t/ 1 h
2. 3 equiv MeI

H

R = cyclopropyl, cyclobutyl or t er t-butyl

R

The alkylehtynyllithium species is first generated by metal exchange with

n-butyllithium under anhydrous conditions, a nitrogen atmosphere and low
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temperature −78 ºC–(−40 ºC). The saccharin is then added dropwise via a
syringe. The reaction is warmed to room temperature overnight. It is then cooled
to 0 ºC and quenched with saturated NH4Cl (aq). It quickly became apparent
that the desired 1,2-benzisothizole 1,1-dioxides were not being formed by this
reaction.
Examination of 1H NMR, 13CNMR and HRMS data suggests a 3,3bisalkylated product (Scheme 7). The 1H NMR spectrum of compound 12 has an
aromatic signal at 7.74–7.75 ppm that integrates to four protons. A multiplet at
1.29–1.20 ppm belongs to the CH in the cyclopropyl group, but integrates to two
protons. The multiplets between 0.81 and 0.68 ppm are signals for the
cyclopropyl CH2 groups, and those integrate to six protons. Furthermore,
compound 12 has a signal at 5.0 ppm which disappears upon addition of D2O,
confirming that this is an exchangeable proton, most probably the NH proton.
Had this been the desired sulfonimine, an exchangeable proton should not be
present nor should there be a 2:1 ratio between the alkyl and aromatic region.
Moreover, the 13C NMR spectrum lacks the imine signal typically observed
around 160 ppm, but it has a peak at 52 ppm. DEPT experiments indicate that
this signal belongs to a quaternary carbon.
To further support the theory that this indeed was the 3,3-bisalkylated
product, all three compounds were submitted to high-resolution mass
spectrometry atmospheric pressure photoionization (HRMS-APPI). The
observed m/z came within either the third or fourth decimal place of the
calculated mass for all three samples. HRMS-APPI is a gentle ionization method
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that does not rely on acid/base reactions to create the molecular ion. Instead,
the sample is passed through a nebulizer where it is bombarded by a UV/vis light
source. A molecular ion radical is then formed by absorption of a photon and
subsequent loss of an electron.
Scheme 7
O O
S
NH

2 R
Li
THF/ -78 C-r.t.

O
O
S
NH 1.1.5 equiv Cs 2CO3 /DMF or CH 3 CN/r.t/ 1 h
2. 3 equiv MeI

O
R
R
12 R = cyclopropyl
13 R = cyclobutyl
14 R = ter t-butyl
O
O
S
N Me
R
R
15 R = cyclopropyl
16 R = cyclobutyl
17 R = t er t-butyl

These results were surprising, especially in that this methodology has
been used in the synthesis of similar 1,2-benzisothiazole 1,1-dioxides, albeit in
low yields.139, 140 Scheme 8 depicts a proposed mechanism for the bisalkylation
reaction. The first step is an acid–base reaction where the acidic N–H proton is
abstracted to form intermediate 8-A. Intermediate 8-A then abstracts from a
proton source. Considering that the reaction is performed under anhydrous
conditions and an aprotic solvent, it is difficult to explain the origin of this proton.
Upon further consideration, it is possible that the reformed alkyne in step 1
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provides the proton source. This forms intermediate 8-B. Attack by another
equivalent of the alkylethynyllithium species affords intermediate 8-C. The
electron pair on the nitrogen then fold back to form imine (8-D) causing an [OH]−
to leave. Another equivalent of the lithium reagent then attacks the imine bond,
and upon workup the bis-(alkylethynyl) product is formed. Scheme 8 depicts a
stepwise mechanism based on the synthetic results observed. Whether
intermediate 8-A does really exist or if the first two steps occur in a concerted
fashion leading to intermediate 8-B remains unclear. What is obvious from the
products isolated is an [OH]− must leave in some form.
Other mechanistic pathways have been considered where the
alkylethynyllithium species attacks the carbonyl first. However saccharin is acidic
with a pKa of ~2.0, and acetylenic protons have pKa of ~25. This suggests that
the first step has to be an acid–base reaction. Another possible mechanism is
shown in Scheme 9. Here the alkylethynyllithium abstracts a hydrogen from
saccharine and forms the lithiated saccharine species 9-A. Another equivalent of
alkylethynyllithium then attacks the carbonyl to give intermediate 9-B. The
protonation of the nitrogen is accomplished by using saccharine which is already
present in solution as the proton soruce. The oxygen electrons then collapse to
reform the carbonyl group and 9-E is formed. Acidic workup gives the
bisalkylated sultam.
The saccharin is added dropwise to the alkylethynyllithium solution, so at
any given moment in time there is an excess amount of lithium reagent relative to
saccharin. We attempted to avoid this dialkylation by adding the lithium species
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to the saccharin, but that only gave the same results with even lower yield due to
the decomposition of the lithium species. Maintaining a low temperature
throughout the reaction and quenching at −78 ºC did not change the results. The
use of alkylethynylmagnesium bromide reagents was unsuccessful at varying
temperatures, and saccharin was the only compound isolated from the reaction
mixture.
Scheme 8
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It was clear at this point that a new approach is needed to accomplish the
task at hand. The new synthetic route shown below (Scheme 10) utilized
methodology developed by Davis and co-workers.140 3-Ethoxy-1,2benzisothiazole 1,1-dioxide is prepared from 3-chloro-1,2-benzisothiazole 1,1dioxide. It is then coupled to the alkylethynyllithium species. Davis and coworkers reported that the success of this method varied depending on the lithium
reagent used. The yields were generally better than the ones reported for the
92

saccharin couplings, but in some cases either very low yields or no product
formation was reported.140 This method was attempted several times, but even
with reflux the reactions did not lead to products.
Scheme 10
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1h

O
O
S
N
O

Cl

X

1.3 equiv. R

Li

-78 C-r.t-reflux

Considering that the chlorine would be a better leaving group than the
ethoxide, a synthetic plan utilizing 3-chloro-1,2-benzisothiazole 1,1-dioxide
directly was put together. Scheme 11 represents the full synthetic route to the
target molecules. Preparation of 1 is accomplished by the molten reaction of
phosphorus pentachloride (PCl5) at 180 ºC, then cooling to 100 ºC and applying
vacuum to remove POCl3 that formed during the reaction. Recrystallization from
hot toluene provided 1 in 78% yield. 1H NMR and 13C NMR spectra were
obtained and matched the expected signals. No NMR data for this compound is
available in the literature. The observed mp is 139–143 ºC, and the value
reported in the literarture is 140–144 ºC.141
This methodology was developed for the synthesis of 2,3-dihydro-3,3dimethyl-1,2-benzisothiazole 1,1-dioxides,142 but has not been reported as a
route for the preparation of 3-alkyl-1,2-benzisothiazoles. The coupling reaction
between 3-chloro-1,2-benzisothiazole (1) and the alkylethynyllithium reagent
proved to be problematic. Initially one equivalent of 3-chloro-1,2-benzisothiazole
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1,1-dioxide was dissolved in dry THF and added very slowly to the lithium
reagent solution at 0 ºC.

Shceme 11

o

R

H

o

1. 1 equiv n-BuLi, -78 C-(-40) C
O
S
2. 1.5 equiv

O

(R,R)-[TSDPEN]RhCp*
S/C 200:1, HCOOH:Et3N (5:2)
r.t.

N
R

1 Cl

O
O
S
NH

O
O
S
N

2 R = cyclopropyl
3 R = cyclobutyl
4 R = ter t-butyl
O
O
S
N Me

1.1.5 equiv Cs2 CO 3/DMF or CH3 CN/r.t/ 1 h
2. 3 equiv MeI

H

H
R

R
5 R = cyclopropyl
7 R = cyclobutyl
8 R = tert- butyl

10 R = tert -butyl
11 R = cyclobutyl

Then the reaction was quenched with saturated NH4Cl (aq) at 0 ºC. The major
products isolated were 3,3-bisalkyl-2,3-dihydro-1,2-benzisothiazole 1,1-dioxides
(compounds 12, 13, 14). All structures were confirmed by 1H NMR and 13C NMR
spectroscopy and HRMS-APPI analysis, and the results matched those of the
products obtained from the saccharin route. Once again the reaction was
attempted at variable temperatures. One equivalent of 3-chloro-1,2benzisothiazole 1,1-dioxide was added at −78 ºC, and the reaction was
quenched at −40 ºC, but no change was observed. The lithium reagent was
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alkylating the chloro pseudosaccharine twice in a mechanism such as that shown
in Scheme 12.
Scheme 12
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The number of 3-chloro-1,2-benzisothiazole 1,1-dioxide equivalents was varied.
Three reactions were run at the same time using 1.1, 1.3 and 1.5 equivalents (1)
to one equivalent of alkylethynyllithium reagent. The reaction temperatures were
maintained at −78 ºC during and after the addition, and the addition rate was
dropwise at a medium speed. The bisalkylated product was once again the
major product; however, the 2-(alkylethynyl)-1,2-benzisothiazole 1,1-dioxide was
also observed. The reaction was monitored by TLC during the addition, and a
new higher migrating spot began to form towards the end of the addition period.
1

H and 13C NMR spectroscopy indicated that this newly observed product is the

desired 3-(alkylethynyl)-1,2-benzisothiazole 1,1-dioxide. The next goal was to
eliminate the formation of the bisalkylated product altogether.
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3-Chloro-1,2-benzisothiazole 1,1-dioxide was dissolved in THF, and it was
poured directly onto the alkylethynyllithium reaction mixture. The flask was
refitted with a septum and a nitrogen line, and it was monitored by TLC for one
hour. It was then quenched with saturated NH4Cl at −78 ºC. The dialkylated
product formation was greatly diminished when 1.1 and 1.3 equivalents were
used as observed by TLC. It formed in small amounts when 1.5 equivalents of 1
were used for the cylopropylethynyl (2) and tert-butylethynyl (4) analogues, but it
was never completely eliminated from the reaction mixture. However, the
dialkylated product formed for the cylobutylethyne analogue regardless of the
number of equivalents used. Although using this technique greatly improved the
yields for these reactions, the overall % yields remained moderate for all three
compounds (2, 3 and 4). Davis and co-workers reported moderate to good yields
depending on the alkyllithium species used.140
2. 2,3-Dihydro-3-(alkylethynyl)-1,2-benzisothiazoles 1,1-dioxides
The next step was the reduction of the imine bond using the rhodium
catalyst (Figure 16) developed by Mao and Baker122, 143 who reported great
success with this catalyst in the enantioselective synthesis of 3-(aryl)-2,3dihydro-1,2- benzisothiazole 1,1-dioxides. According to Mao and Baker the R,Rcatalyst gave the S stereochemistry and vice versa. However, they observed
that this
trend decreased and was completely reversed as the size of the C-3 group
decreased.
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Ts
N
Rh
N
H2

Cl

Figure 16. Structure of ((R,R)-N-(p-tolunesulfonyl)-1,-2diphenylethylenediamine)-rhodium-(pentamethycycopentadienyl)-Cl ((R,R)[TSDPEN]RhCp*Cl).
Initially methodology developed by Mao and Baker was used. While the
reaction conditions seemed to work, reaction times were 6 h. Reduction of
compound 4 into 8 proceeded smoothly with good yields (60%). Reductions of
3-(aryl)-1,2-benzisothiazole 1,1-dioxide proceeded with much higher yields.
During the purification process, it became apparent that the benzisothiazoles
contained small amounts of the bisalkylethynyl products which may explain the
lower yield in the desired product since our starting material was not 100% pure.
Complete separation of these compounds was successful. Reduction of 2 and 3
into 5 and 7, respectively, (Scheme 13) was not successful. The 1H NMR
spectra of the new compounds have unexpected signals in its aliphatic region.
The two new signals integrate to 2H each suggesting —CH2 groups. The 13C
NMR spectrum lacked the alkyne signals observed in the other 1,2benzisothiazole-3-(tert-butylethynyl)-2,3-dihydro 1,1-dioxide (8) and had two new
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signals in the aliphatic region as well. The observed m/z for compound 5 [M+H]+
is 238.0907 (234.0510) and for compound 7 250.969 (247.067) an increase of
four units or four hydrogens. All of these results help prove that the compounds
obtained from this reduction are the 3-(cyclopropylethyl)- and 3-(cyclobutylethyl)1,2-benzisothiazole 1,1-dioxides. To avoid the reduction of the alkyne moiety,
variable reaction conditions were attempted. The reaction was first monitored by
low resolution EIMS. Small aliquots of the reaction at 20 min, 30 min and 60 min
were taken, and no trace of the desired compound was found. The isolated
products after 30 minutes and up were that of the over-reduced compounds 6 or
23 (Scheme 13).
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The active form of the catalyst is the Rh-hydride species. The pre-catalyst
shown in Figure 16 is converted to the active catalyst by hydride transfer from
the formate ion present in the azeotropic mixture onto the metal center with loss
of a chlorine ion. The catalyst was dissolved in a small amount of dry
dichloromethane, and one equivalent of azeotropic mixture was added. Carbon
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dioxide gas bubbles were observed, as CO2 is released as the formate ion loses
a hydride to the metal center to form the active complex. The mixture was
stirred for 10 min, and then a solution of compound 2 or 3 in dry dichloromethane
and one equivilant of formate to substrate were added. A color change from red
to a dark brown color was observed within 15 min. The reaction was quenched
and purified, and only starting material was recovered. This procedure was
repeated several times with varying reaction times (30, 60, 120 min). The only
product isolated, if any, was compound 6 or 23. As mentioned above, the
reaction was complete at approximately 2.5 h. Compounds 6 and 23 exhibited no
optical activity. The reason for the reduction to the alkyl compound is not known
at this time.
3. 3-(Alkylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1-dioxide
Methylation of compounds 6, 23 and 8 into compounds 12, 24, and 10,
respectively, was carried out using Cs2CO3 as base and iodomethane as the
methylating reagent in either N,N-dimethylformamide (DMF) or acetonitrile. The
reactions proceeded to completion at room temperature. The synthetic route
followed by Mao and Baker employed DMF as a solvent system due to the
solubility of Cs2CO3 in DMF. Cs2CO3 was found to be equally soluble in
acetonitrile, and the reactions proceeded to completion. The use of acetonitrile is
more convenient because DMF is difficult to remove from the reaction mixture.
The progress of the reaction was monitored by TLC, and surprisingly two
spots were observed. Both spots ran closely to each other much like two
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diastereomers of the same compound. Both spots were collected together, and
their 1H NMR and 13C NMR spectra were obtained. The 1H NMR spectrum of 10
contained two H3 and two N-CH3 signals. HRMS-APPI for 2,3-dihydro-2-methyl3-(tert-butylethynyl)-1,2-benzisothiazole 1,1-dioxide (10) observed only one m/z
at 262.0933 (262.0902). HRMS-APPI for 2,3-dihydro-2-methyl-3(cyclopropylethyl)-1,2-benzisothiazole 1,1-dioxide (12) and for 2,3-dihydro-2methyl-3-(cyclopropylethyl)-1,2-benzisothiazole 1,1-dioxide failed. No other
significant peaks were observed. Apparently 3-alkyl-2-alkyl-1,2-benzisothiazoles
do not easily ionize. Variable light source intensities did not cause these
compounds to ionize. However, 1H NMR and 13C NMR spectra clearly indicate
the expected structures. Further analysis would be needed for these
compounds.
4. A complete analysis of 10
Both components of compound 10 were successfully isolated. The fastmigrating spot is designated 10a, and the slower migrating spot is referred to as
10b. Recrystallization of these two spots was only successful for 10a. When
compound 10b was resdissolved for recrystallization, a TLC sample was taken,
and two spots reappeared. When the crystals of 10a were redisolved for 2D
NOESY experiments, a 1D 1H NMR spectrm was obtained. From this spectrum it
was determined that the signal at 5.59 ppm is H3 for 10a, and the signal at 3.12
ppm belongs to the N-methyl protons in 10a. As the sample remained in
solution, the other two signals reappeared, and TLC indicated the formation of
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10b again. 2D NOESY experiments were run on the mixture. A cross peak
between the singlet at 5.99 ppm and the singlet at 3.12 is observed, but no cross
peak is observed between the singlets at 6.13 ppm (H3 in 10b) and 3.21 ppm
(CH3 in 10b). These results confirm that the orientation of the methyl group on
the nitrogen varies between 10a and 10b and that H3 in 10a is clearly within 5 Å
or less from the methyl group on the nitrogen, while H3 in 10b is more than 5 Å
away. From these results one can hypothesize that 10a and 10b are
conformers of the same molecule. HRMS-APPI analysis only show the m/z
expected for 10. Other sultams have been reported to exhibit such a phenomena
where two conformers are in equilibrium in solution.144 To further support our
hypothesis, variable-temperature 1H NMR experiments were carried out (Table
13). Our attention was focused on the N-CH3 singlets at 2.38 ppm and 2.24 ppm.
The two methyl group signals clearly show movement toward coalescence as the
temperature rises. At 300 K the ∆ ppm between the two signals is at 0.14 ppm. A
gradual decrease in the difference between the two peaks and a slight
broadening of the peaks was observed as the temperature increased. The
highest temperature reported here is 405 K. Unfortunately, at 410 K, the probe
temperature would not stabilize. To avoid the risk of overheating the probe, the
experiments was halted. The exact coalescence point was not observed. The
results observed exhibit enough of a patern to conclude that the methyl signals
were indeed coalescing.
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Table 13. VT 1H NMR experimental results
Temperature (K)

N-CH3 (10a)

N-CH3 (10b)

∆ (ppm)

300

2.38

2.24

0.14

315

2.45

2.33

0.12

350

2.62

2.54

0.08

365

2.70

2.63

0.07

380

2.77

2.71

0.06

390

2.81

2.77

0.04

395

2.82

2.78

0.04

400

2.82

2.79

0.03

405

2.86

2.83

0.03

5. 3,3-Bis-(alkylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothiazole 1,1dioxide
Although the 3,3-bis-akylated compounds were not synthetic targets for
this project, they were methylated as well. They were also docked into reverse
transcriptase and evaluated for potential anti-HIV activity. The methylation
reactions for compounds 12,13 and 14 afforded compounds 15,16 and 17,
respectively, in very good yields (Scheme 4). NMR spectroscopy and HRMSAPPI confirmed these structures.
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C. Modeling of 3-(m-cyclopropylpheynyl)-2,3-dihydro-2-methyl-1,2benzisothiazole 1,1, dioxide (m-cyclopropylpheny sultam 18) and 2,3dihydro-3-(isopropylfuranyl)-3-methyl-1,2-benzisothiaozole 1,1-dioxide
(isopropylfuranyl sultam 19)
Another series of compounds were docked into wt RT and Y181C (Figure
17). The structures were inspired by the original sultam NSC-108406. Both of
these sultams have first generation NNRTI structural features. Both have two
aromatic rings that form the π and the extended π systems. Both have a
substituted ring C on position-3 or the meta-position. The unique feature of 19 is
that the extended π system in ring C is a heterocyclic ring. This compound was
designed with Y181C RT in mind. Since loss of activity in mutant RTs is
attributed to loss of pocket hydrophobicity, and therefore loss of major binding
interactions, it was hypothesized that a heterocyclic ring may be able to form a
hydrogen bond with CYS181.

O
O
S
N Me

O O
S
N Me

H

H
O

18

19

Figure 17. Sultams inspired by NSC-108406.
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The methyl group in NSC-108406 was substituted with a cyclopropyl
group in the meta-position. This was inspired by efavirenz and its high activity
against wt RT and its sustained activity against mutant RT strains. Compound
18 was docked into the wt RT and Y181C. Tables 14 presents FlexiDock results

for 18 in wt RT. In the wt RT pocket the distances observed are quite interesting.
Each ring in the ligand makes close contacts with specific residues, and each
residue is within 4–5 Å of one of these rings. This ensures that all key residues
are bound to a part of the ligand. Whether this means this inhibitor will be more
tightly bound to the pocket remains to be seen through biological activity studies.
The cyclopropyl ring makes two close contacts with Tyr181 (3.94 Å) and Trp229
(4.37). Ring C, on the other hand, makes a close contact with Tyr188 (4.37 Å).
All three residues are essential for NNRTI binding to wt RT. Unfortunately
SYBYL does not predict a hydrogen bond with Lys101 (3 Å). Although this
compound is not considered to be structurally related to efavirenz, its orientation
was still compared to efavirenz in the pocket. Visual inspection of docked
models do not show much similarity between the binding conformations of the
two compounds, but based on the measured distances of 18 and the observed
distances of efavirenz/wt RT crystal structure, both cyclopropyl groups make very
close contact with Tyr181 (Figure 18). And both are 4.5 Å or less away from
Trp229.
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Table 14. Presents the results for m-cyclopropylphenyl sultam (1) in wt RT.

Ligand

Residue

Distance

SO2

Lys101

3.39

Cyclopropyl

Tyr181

3.94

Tyr183

7.59

Tyr188

5.93

Trp229

4.35

Tyr181

5.98

Tyr183

8.84

Tyr188

4.37

Trp229

5.55

Tyr318

5.108

Ring C

Ring A
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Figure 18. 3-(m-Cyclopropylphenyl) sultam in wt/efavirenz RT complex
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Docking into Y181C provided the results reported in Table 15.
Unfortunately no hydrogen bond was predicted for 18 with Lys101 (3.34 Å).
Much like the alkylethynyl series, the cyclopropyl group makes a stronger contact
with Tyr188 (3.78 Å) than in the wt pocket (5.18 Å). This is due to the loss of the
large aromatic interaction with Tyr181 as it mutates to Cys181. Noticeably the
distance between the cyclopropyl ring and Trp229 drops under 4 Å in the Y181C
pocket. The cyclopropyl ring also makes a significant change in its orientation
towards Tyr183 (Figure 19). Until now all the contacts observed between the
alkyl/cycloalkyl inhibitor groups located in wing 2 of the pocket have been over 5
Å. This was expected as Tyr183 is involved in pocket formation rather than
direct binding. However the cyclopropyl group in 18 moves closer to Tyr183
(4.73 Å) a drop in distance of almost 3 Å compared to the wt RT pocket (7.59 Å).
This observation is completely opposite to the trend reported in efavirenz and all
the docked sultams. Upon loss of the aromatic Tyr181 to Cys181, these
inhibitors seem to move towards wing 1. This was characterized by the decrease
in distance with Tyr318 and Lys101, as well as the hydrogen bond predictions
observed in some. Compound 18, however, reorients itself in the hydrophobic
region so that it makes more hydrophobic contacts with other aromatic residues
such as Tyr183. The cyclopropyl group is popular in drug design due to its
unique electronic feature. Cyclopropyl groups have a slight sp2 character
allowing them to behave as π-systems; therefore, their interactions with aromatic
rings can be considered π–π interactions.
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Table 15. m-Cyclpropylphenyl sultam (18) ligand–residue in Y181C RT pocket.

Ligand

Residue

Distance

SO2

Lys101

3.34

Cyclopropyl

Cys181

—

Tyr183

4.73

Tyr188

3.78

Trp229

3.98

Cys181

—

Tyr183

7.88

Tyr188

4.21

Trp229

5.20

Tyr318

5.89

Ring C

Ring A
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Figure 19. m-(Cyclopropylphenyl) sultam (18) in Y181C RT superimposed with
efavirenz.
3-(Isopropylfuranyl) sultam (19) was also docked in wt RT and Y181C RT.
Compound 19 adopts a similar orientation in the wt pocket as 18. The isopropyl
group makes contact with Trp229 at a distance of less than 4 Å. No hydrogen
bond is predicted, and the distance calculated between the sulfonyl group and
Lys101 is 3.25 Å. In general this compound does not have any unique features
in its binding conformation that sets it apart from the other inhibitors. Table 16
and Figure 20 show the results of the docking experiments.
In the Y181C RT pocket the most important change noted is the
orientation of the furan ring oxygen. After several FlexiDock experiments, the
oxygen in the furan ring was always oriented towards the SH in Cys181(Table 17
and Figure 21).
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Table 16. FlexiDock results for isopropylfuranyl sultam in wt RT.

Ligand

Residue

Distance

SO2

Lys101

3.25

Isopropyl

Tyr181

5.74

Tyr183

7.72

Tyr188

4.63

Trp229

3.76

Tyr181

6.07

Tyr183

9.78

Tyr188

4.79

Trp229

6.79

Tyr318

5.19

Ring C

Ring A

110

Figure 20. 3-(Iso-propylfuran) sultam (green) in wt/efavirenz RT(white).

.
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Table 17. 3-(Isopropylfuranyl) sultam (19) ligand–residue distances in Y181C
RT.
Ligand

Residue

Distance

SO2

Lys101

3.16

Isopropyl

Cys181

–—

Tyr183

7.02

Tyr188

5.18

Trp229

3.89

Isopropyl Oxygen

Cys181

3.33

Ring C

Tyr183

8.89

Tyr188

4.55

Trp229

6.72

Tyr318

5.03

Ring A
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Figure 21. 3-Isopropylfuranyl sultam (19) in Y181C/efavirenz RT.
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This is almost a 180º rotation from its position in the wt RT pocket. The distance
observed between the oxygen and the Cys181 SH is 3.33 Å. No hydrogen bond
is predicted; however, the repeated observation of this result in varying
experiments suggest some sort of interaction occurring.
D. Modeling of a Rhodium Catalyst

Mother Nature seems to have mastered the most simple and complex of
reactions in the most elegant pathways. Oxidoreductases such as alcohol
dehydrogenases catalyze transfer hydrogenations to convert carbonyl
compounds into alcohols using NADH or NADPH as cofactors.145 These
reactions are usually extremely stereoselective. However, organic chemists
have yet to master the ease in which nature can produce enatiomerically pure
compounds. Organic synthesis requires economical and practical reagents that
can be utilized at different reaction scales. Catalytic-transfer hydrogenation has
received much attention in recent years. The search for nonhazardous
enantioselective metal catalysts for transfer hydrogenation dates back to 1976
when Imai and co-workers reported hydrogen transfer from organic compounds
to ketone and aldehydes catalyzed by dihydrotetrakis(triphenylphosphine)ruthenium(II) (RuH2(PPh3)4).146 The process remained primitive and not very well
understood until recently. Efforts from Pfalts,147Genet,148 Lemair149 and Evans150
produced respectable results, but these reactions were limited by their low
enantioselctivity and catalytic activity, as well as low substrate-to-catalyst ratios
(S/C). In recent years ruthenium complexes have been improved to overcome
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H
P H P
t-Bu t-Bu
(S,S,R,R)-TangPhos

Figure 22. Structure of TangPhos ligand.

the low reactivities and enantioselectivities observed in these reactions.122, 145, 151
The most recent work in the area of hydrogen-transfer catalysis comes
from Yang and co-workers. They use palladium-diphosphane complexes for the
hydrogenation of N-tosylimines. They found that palladium-TangPhos (Figure 22)
catalyzed hydrogenations most efficiently compared to other complexes used.
Reactions proceeded with 99% ee and excellent yields.152
The saccharin-based synthetic route developed by Baker and co-workers
(Scheme 3) for the synthesis of a variety of sultams required an enantioselective
reduction of C=N double bonds. Mao and Baker found that the commercially
available RhCp* complex reduces imines into racemic amines under mild
conditions. They then developed a chiral Rh catalyst for the asymmetric transfer
hydrogenation of imines into chiral amines.122
Pentamethycylopentadienylrhodium chloride was compbined with (1R,2R)-N-(ptolunesulfonyl)-1,2-diphenylehthylenediamine [(1R,2R),-TSDPEN] in
dicholormethane and triethylamine to give the desired complex 20. 1H NMR and
13

C NMR spectroscopy, along with single crystal X-ray crystallography were used

to fully characterize the structure of 20 (Figure 23).
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Ts
Rh N
Cl
N
H2

Figure 23. Structure of R,R-20
The best reaction conditions utilized an azeotropic mixture of formic
acid/triethylamine (5:2) with a 200:1 substrate-to-catalyst (S/C) ratio. For the
sultam series the presence of an aryl group on position 3 was found to affect the
stereoselectivity. R,R-20 gave the S enantiomer when C3 had an aromatic group;
however, these results were complete opposites when C3 was substituted with a
methyl or small alkyl group.122
In order to understand the stereoselectivity of this catalyst, a full
characterization of the catalytic cycle is needed. Bragg and co-workers in
collaboration with Baker and co-workers were able to propose a catalytic cycle
through 1D, 2D and variable low-temperature NMR experiments.153 Scheme 14
shows the catalytic cycle as proposed by Bragg et al.153 The catalytic cycle
begins with the formation of the activated hydride species. The imine sultam (3(aryl)-1,2-benizothiazole 1,1-dioxide) then approaches the catalyst. Hydrogen
transfer occurs, and the reduced sultam is bound to the catalyst. The newly
reduced sultam is then released, and it is thought that the solvent stabilizes the
ionic rhodium complex formed until another formate ion binds to the metal center
to form the hydride species and the cycle continues.
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Ph

Ts
N

Ts
N

Ph

N
H

Rh Cp* + H 2(g)

Rh
Cl

NH 2

Ph

Ph
Cp*

19

O
Ts
N

Ph

Cp*

O
S N

Rh

(g)
CO 2

H

NH 2

Ph

Hydride: 1
O

H
O
H
HN
O S
O

Cationic Species: 4
Ph

Ts
N

Cp*

Ph

Cp*

Ph

NH 2

NH2
S

Ph

Cp*

Ts
N

OH

Bound Sultam: 2
Ph

Ts
N

Rh

Rh

Rh
Ph

O
H

Ts
N

N
H

Ph

H
O HN
S
O

Ph

NH2

Cp*

Rh H
O

N
S

O

S = Solvent

Reduced Bound Sultam: 3
Ph
H
HN
O S
O

Ph

117

Ts
N
NH2

Cp*

Rh H
O HN
S
O

H+

Modeling studies were employed in an attempt to further understand the catalytic
cylcle and explain the stereoselectivity observed. Employing the same principles
used in inhibitor/enzyme docking experiments, molecular dynamic studies were
performed on the docked imine sultam.
In order to explain the stereoslectivity of the catalyst, a series of imine
sultams were docked in two different approaches. The “original” and the
“reverse” approach. The original approach is the conformation leading to the
enantiomer reported to be the major one produced experimentally. The reverse
approach is the conformation leading to the other enantiomer, which was either
not observed or observed in low yield.122
The studies reported here present initial results. A survey of the literature
indicated that the use of Tripos ff and the SYBYL package in such modeling
studies is completely novel. The Tripos ff comes with a set of metal parameters
typically used in biological systems such as Mg, Ca, Mn and Co. To be able to
use the Tripos ff in this project, the rhodium catalyst parameters needed to be
added to the force field parameter files. The lack of literature on modeling
studies for similar rhodium catalysts led to a different approach.
The basic rhodium parameters were obtained from the Tripos metal
parameters files that accompany the SYBYL package (Table 18). These
parameters only supplied the essential information for the force field to recognize
the atom and include it in calculations. Second, a search of the Cambridge
Crystal Structure Database (CCDC) was performed to find different bond angles
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Table 18. Rhodium metal parameters from the SYBYL databse.

Parameter Name

Parameter Value

Mnemonic atom type

“Rh”

Heteroatom Symbol

“Rh”

Valence

6

Geometry

OH (octahedral)

Equivalent atom type

Cr.OH (chromium octahedral)

Atomic number

45

Color code

Yellow

Can der Waals radius

1.69

Formal charge

0

Electronegativity

2.28

H–bond Donor

NO

H–bond Acceptor

NO

Lone Pair

0

Temp factor

9.00

Atomic weight

102.9.05

Sybyl 3.x atome type ID

926

Sybyl 3.x mnemonic atom type

“Rh”
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and bond lengths for similar complexes. The mean of each value was taken and
used as a constraint in energy calculations. This helped guide the Tripos ff and
stopped illogical and extremely high energy structures from being produced.
Table 19 lists the mean bond angles and bond lengths from the CCDC search.
A preliminary study on several crystal structures of similar Rh complexes
was carried out. All complexes were subjected to the Tripos ff minimizations,
and the bond angle and bond lengths were monitored. Structures with
unreasonable bond angles or bond lengths, or bent aromatic ring were not used
in further calculations. Typically these structures have higher energies than the
other conformations. The results observed were very encouraging. RMS values
were never larger than 0.056, and bond angles and lengths did not change too
much from the values observed in the crystal structures. The focus then turned
onto the synthetically relevant (R,R)-[TSDPEN]Rh-Cp*-Cl ((R,R)-20).
The R,R-20 crystal structure was downloaded from the Cambride
Crystallographic Data Centre (CCDC, code WOLCOP). Bond constraints were
only applied for the Rh–Cp* lengths. Bond-angle values for NH–Rh–NTs, NH–
Rh–Cp*, NTs–Rh–Cp*, Cl–Rh–NH, Cl–Rh–NTs were constrained to the mean
values in Table 19 . A minimization was performed using the Tripos force field
and Gasteiger–Hückel charges. In the first calculation no rigid structures were
defined. This led to a strained Rh–Cp* bond and a higher energy than the initial
crystal energy. To avoid this problem, the Rh–Cp* bonds were defined as “active
aggregates”.
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Table 19. CCSD bond length and bond angle search results.
Bond Lengths
Bond

Mean Bond Length (Å)

Rh–Cl

2.43

Rh–N

2.11

Rh–Cp*

1.78
Bond Angles

Angle

Mean Value (º)

N–Rh–Cl

87.77

N–Rh–N

78.07

N-Rh–Cp*

130.84

Cl-Rh-Cp*

125.34
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Members of an active aggregate are minimized together as one unit. This
was necessary, because the Tripos force field did not have a bond definition for
the Cp*–Rh bonds. It is worth noting that constraining bond lengths between
these two entities was not enough, as the aggregate was needed in order for
reasonable structures to be produced. It is important to remember that
aggregates are not “rigid”, i.e., they do not move. Figure 24 depicts the crystal
structure of R,R-20 and its minimized structure superimposed on top of each
other with an RMS value of 0.055. Table 20 reports the crystal structure and
minimized structure bond lengths and bond angles. The initial energy is observed
to be 504.463 kcal/mol, and the final energy is 338.266 kcal/mol. Although these
energy values have no physical meaning, they are used as points of reference.
Observing an energy drop is good, as this means the calculations are producing
positive results.
Next we substituted the chlorine atom in the crystal structure with a
hydrogen and ran the same minimization on the R,R-20H (the hydride species is
the active form of catalyst). The initial energy of the complex was 676.41
kcal/mol, and the final energy was 343.54 kcal/mol. Figure 25 presents the
minimized R,R-20H superimposed on the R,R-20 crystal structures (RMS =
0.036) Table 21 compares bond lengths and angles between the crystal structure
and the hydride species. Table 21 reports the crystal and minimized hydride
bond lengths and angles. The results observed are comparable to those
observed in the minimized R,R-20 structure.
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Figure 24. R,R-20 crystal (white) superimposed on R,R-20 minimzied (violet).
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Table 20. Crystal vs. minimized bond lengths and angles for R,R-20

R,R-Cl
Bond Lengths

Crystal

Calculated

∆

Rh-NTs

2.186

2.096

0.09

Rh-NH

2.102

2.064

0.038

Rh-Cl

2.412

2.188

0.224

Rh-Cp*

1.832

1.832

0

NTs-C1

1.473

1.448

0.025

NH-C2

1.481

1.475

0.006

NTs-Rh-NH

77.27

77.34

-0.07

Nts-Rh-Cl

94.01

94.01

0

NH-Rh-Cl

84.09

84.14

-0.05

Nts-Rh-Cp*

130.26

130.39

-0.13

NH-Rh-Cp*

129.85

129.97

-0.12

Nts-C1-C2

108.14

104.96

3.18

Nh-C2-C1

106.87

110.1

-3.23

Rh-Nts-C1

113.42

115.71

-2.29

Rh-Nh-C2

108.68

102.53

6.15

Angles
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Figure 25. R,R-20H (violet) superimposed on R,R-20 after minimization.
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Table 21. Hydride vs. crystal bond lengths and angles.
Bond Lengths

Crystal

Calculated

∆

Rh-Nts

2.186

2.106

0.08

Rh-NH

2.102

2.079

0.023

Rh-H

(Rh-Cl)2.412

1.025

1.387

Rh-Cp*

1.832

1.832

0

Nts-C1

1.473

1.448

0.025

NH-C2

1.481

1.476

0.005

Nts-Rh-NH

77.27

77.33

-0.06

Nts-Rh-Cl

94.01

94

0.01

NH-Rh-Cl

84.09

84.14

-0.05

Nts-Rh-Cp*

130.26

130.37

-0.11

NH-Rh-Cp*

129.85

129.95

-0.1

Nts-C1-C2

108.14

105.15

2.99

Nh-C2-C1

106.87

110.4

-3.53

H-Rh-Cp*

125.31

125.09

0.22

Angles
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Please note the the crystal contains a Rh–Cl while the minimized hydride
catalyst contains Rh–H bond. It would be expected to observe a significant
difference between these two bonds. Our results indicate that the Rh–H bond
length is 1.025 Å. The Rh–Cl bond length is almost double that. These results
are considered acceptable and reasonable.
The new parameter files for the Tripos force field were loaded. The
minimized R,R-20H and 3-(m-methylphenyl)-1,2-benzisothiazole 1,1-dioxide (21)
were retrived (Figure 26).
Compound 21 (refered to as imine sultam) was docked into the catalyst
cavity using the Dock program in SYBYL. The Dock program is a manual
docking program. The “enzyme”/catalyst and inhibitor are each identified. The
catalyst was then fixed in space, and the inhibitor’s position was adjusted into the
cavity. An interactive dialogue box keeps track of steric and electrostatic energies
as the inhibitor’s position is adjusted. The imine substrate position was adjusted
to give the lowest energy possible.

O
O
S
N

Me

21

Figure 26. Structure of 3-(m-methylphenyl) 1,2-benzisothiazole 1,1-dioxide (21).
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Two docking experiments were carried out. In the first docking
experiment, the imine sultam is positioned so that its sulfonyl group is towards
the catalyst NH2 moiety (Figure 26 A). In the second experiment the sulfonyl
group is docked toward the N–Ts moiety; this conformation will be refered to as
“reverse” (Figure 26 B). Yamakawai and co-workers published two studies that
dealt with chiral η6–arene–ruthenium(II) complexes.154, 155 In molecular orbital
calculations they attempted to identify the mechanisms of action by which
asymmetric transfer hydrogenation of carbonyl compounds catalyzed by these
complexes proceed.154 They also performed density functional theory-based
(DFT) studies to shed some light on the origin of enantioselectivity in these
reactions.155 Based on their DFT studies they predicted that in aryl ketones CH/π
interactions between the arene ring and aryl ketone are the basis of
enantioselectivity. According to their findings the R,R-catalyst gives the R alcohol
and vice versa. The rhodium catalyst in question affords the exact opposite
selectivity in imine reductions, especially when a bulky aromatic ring exists on
ring C. (Refer to figure 6.)
In the original approach in the docking experiment, it is assumed that
CH/π interactions do occur. The “reverse” docking conformation assumes that no

π interactions govern enantioselectivity. The substrate/catalyst complex is then
converted to a FlexiDock input file. This is only done to create a file with both
catalyst and substrate in the same molecular area. This is essential in order to be
able to minimize the complex as one unit. A molecular dynamics experiment is
then performed using the same specifications for aggregates and distance
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A

Final E = 331.175 kcal/mol

B
Final E = 340.93 kcal/mol

Figure 27. (A) imine substrate docked into R,R-20H. (B) imine substrate docked
in “reverse” mode
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constrains as before. The energies between the two possible substrate
approaches are reported and compared. Figure 27 displays both docked
conformations with the final energies for each. The final energy of the docked
imine sultam is lower than that of the “reverse” conformation, with a difference of
~10 kcal/mol observed between these two complexes. The first complex leads to
the S stereochemistry on the sultam while the second leads to the R.
Experimentally, the S enantiomer is the major product isolated from this
reaction. The energy difference observed could explain why the original
approach is preferred. The R or “reverse” approach is relatively higher in energy
and therefore is expected to be a minor contributing structure along the
conversion pathway.
Next n-butylimine (22) and methyl imine (23) (Figure 28) were docked into
the catalyst cavity in both the “original” approach and the “reverse approach.
The energy of the first approach which leads to the R enantiomer is 126 kcal/mol,
and the energy of the “reverse” approach is 117 kcal/mol, which is a difference of
9 kcal/mol. For a small molecule system a change of ~10 kcal is considered
significant. Based on these observations the R enantiomer should produce the
major product. Indeed this is observed experimentally (Figure 29 and Figure 30
show both approaches).122
Compound 23’s results also matched its experimental observation. The
“reverse” approach produced the lowest complex energy. This approach leads to
the formation of the R enantiomer a result that agrees with the experimental
results reported by Mao and Baker.122
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Figure 28. n-Butyl imine (22) and methyl imine (23).
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Final E = 126.369 kcal/mol

A

B

Final E = 117.417 kcal/mol

Figure 29. n-Butyl imine sultam in R,R-20H cavity. (A) original approach, (B)
reverse approach
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A

Final E = 132.517 kcal/mol

B

Final E = 120.24
kcal/mol

Figure 30. Methyl imine sultam in R,R-20H (A) original approach; (B) reverse
approach.
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3-(Cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide was also docked
into the catalyst cavity. Figure 31 shows both original and “reverse” approach.
The calculated energy for the original approach is 441.23 kcal/mol and for the
reverse approach 434.62 kcal/mol. Based on the pattern observed in the
previous docking experiments, the R stereochemistry should be preferred.
However, synthetic studies yielded products with no optical activity, which
indicates that the catalyst did not enantioselectively reduce the imine bond.
Moreover, for the cyclopropyl and cyclobutyl analogues, the alkyne was also
reduced to the alkane. The tert-butyl analogue was found to be optically inactive;
however, its triple bond remained intact. This is probably due to steric hindrance
as the tert-butyl group is bulkier than the small ring structures.
The modeling studies presented above are considered only initial
modeling studies. We used these compounds to establish the best parameters
for such experiments. It was very disappointing to find that not only did the
catalyst not reduce the alkylethynyl sultam series stereoselectively, but it also
reduced the alkyne bond into an alkyl bond for two out of three of the target
compounds. It is clear from the experimental results that the approach of
substrate to catalyst is greatly governed by steric effects. In the future further
mechanistic studies are needed. A study of different substrates with a wide
variety of substituents at C-3 is also required in order to determine when the
catalyst exactly switches from stereoselectively producing S to producing
racemic mixture, to stereoselectively producing R.
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Final E = 441.23

Final E = 434.62 kcal/mol

Figure 31. Cyclopropylethynyl imine sultam in catalyst cavity. (A) direct
approach; (B) reverse approach.
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III. Experimental
Preparation of 3-(chloro)-1,2-benzisothiazole 1,1-dioxide (1)
In a dry round bottom flask equipped with a stir bar and an air condenser were
placed 4.05 g (22.1 mmol) of saccharin and 5.88 g (28.6 mmol) of PCl5. The
apparatus was fitted with an inlet nitrogen line and an outlet vent to allow release
of gas build up into the fume hood and the mixture was heated to 80 ºC. Once
the reaction changed from cloudy to clear, the temperature was raised to 175 ºC
for 2 h. At the end of the 2-h period, the reaction mixture was cooled to 100 ºC
and a vacuum was applied to remove the POCl3. The reaction was left to cool to
room temperature while under vacuum and when at room temperature the
vacuum was maintained for another 1 h. A pale yellow solid formed. It was
recrystallized from hot toluene to give a white fluffy solid (3.5 g, 79% yield): mp
(139-143 ºC; lit. 140–144) 1H-NMR (300 MHz, CDCl3, 25 ºC): δ 7.8–8.4 ppm (m,
4H, aromatic).

13

C NMR (300 MHz, CDCl3, 25 ºC): δ 166 (C3), 140.5 (C9), 134.9

(C8), 134.4(C7), 129.8 (C4) 125.1 (C5), 122.5 (C8).

3-Ethynylalkyl 1,2-benzisothizoles 1,1-dioxides
In a dry flask was dissolved 2.0 mmol of the respective alkyne in 6 mL of freshly
dried THF. The solution was stirred and cooled to −78 ºC under anhydrous
conditions and a nitrogen atmosphere. One equivalent of 2.2 M n-BuLi solution
in THF (0.9 mL) or 1.6 M MeLi in THF (1.25 mL) were then added via a syringe.
The reaction was left to stir for 4 h and then warm to −40 ºC. It was then cooled
to −78 ºC, and a solution of 0.643 g (1.5 equiv.) 3-chloro-1,2-benzisothiazole 1,1dioxide in dry THF was quickly poured into the reaction. The flask was refitted
136

with a septum and a nitrogen line, and the coupling reaction mixture was left to
stir at −78 ºC for 1 h. It was monitored by TLC. After 1 h , 5 mL of satd aq NH4Cl
was added to quench the reaction at −78 ºC. The mixture was left to warm to
room temperature overnight, and a white precipitate formed. The biphasic
mixture was then filtered and separated. The organic layer was washed with 1.0
M NaHCO3 (2 x 5 mL). It was dried over anhyd. MgSO4, vacuum filtered and
rotary evaporated. The desired product was purified using silica gel column
chromatography eluting with a gradient solvent system starting with 5% acetone
in petroleum ether to 10% acetone in petroleum ether (for the butylethynyl
analogues 4 and 5) or 15% acetone in petroleum ether (for the cyclopropylethnyl
analogue 3).

3-(Cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide (3)
Yield: 0.177 g (40% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.89–7.73 (m,
4H, CH, ArH), 1.64–1.74 (m, 1H, CH-cyclopropyl), 1.10–1.21 (m, 4H, CH2cyclopropyl).
13

C NMR (300 MHz, CDCl3, 25 ºC): δ 156.54 (C-3, C=N), 138.71 (C-9, CH, Ar),

133.86 (C-6, Ar), 133.74 (C-7, Ar), 131.36 (C-4, Ar), 125.04 (C-5, Ar), 122.11 (C8, Ar), 115.77 (C-1', alkyne), 68.79 (C-2', alkyne), 10.97 (C-4',C-5', cyclopropyl),
1.11 (C-3', cyclopropyl). HRMS-APPI (m/z): [M+H]+ calcd for C12H10NO2S,
232.0432; found, 232.0424.

3-(tert-Butylethynyl)-1,2-benzisothiazole 1,1-dioxide (4)
Yield: 0.140 g (47% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.92–7.68 (m,
4H, CH, ArH), 1.46 (s, 9H, CH3, t-butyl). 13C NMR (300 MHz, CDCl3, 25 ºC): δ
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156.81 (C-3, C=N), 138.68 (C-9, CH, Ar), 133.97 (C-6,CH, Ar), 133.82 (C-7,
CH,Ar), 131.31 (C4,CH, Ar), 125.05 (C-8, Ch, Ar), 122.11 (C-5, CH, Ar, 118.59
(C-2′, C≡C), 71.51 (C-1′, C≡C), 29.95 (3CH3, t-Bu), 28.99 (-C(CH3)3, t-But).
HRMS-APPI (m/z): [M+H]+ calcd for C13H14NO2S, 248.0745; found, 248.0731.

3-(Cyclobutylethynyl)-1,2-benzisothizoles 1,1-dioxide (5)
Yield: 0.185 g (43% yield). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.9–7.60 (m, 4H,
CH, ArH), 3.31–3.29 (m, 1H, CH-cyclobutyl), 2.24–1.80 (m, 6H, CH2-cyclobutyll).
13

C NMR (300 MHz, CDCl3, 25 ºC): δ 157 (C-3, C=N), 138.59 (C-9, CH, Ar),

133.99 (C-6, Ar), 133.89 (C-7, Ar), 131.26 (C-4, Ar), 125.015(C-5, Ar), 122.10 (C8, Ar), 114.23.77 (C-1', alkyne), 89.01 (C-2', alkyne), 19.42–18.16(C-4',C-5', C-6′,
cyclobutyl , 0.97 (C-3', cyclobutyl). HRMS-APPI (m/z): [M+H]+calcd for
C13H14NO2S, 245.051; found, 245.062.

3-(Cyclopropylethyl)-2,3-dihydrdo-1,2-benzisothiazole 1,1-dioxide (6)
In a dry round-bottom flask equipped with a stirring bar and a nitrogen line was
dissolved 1.9 mg of (R,R)-[TSDPEN]RhCp* in 1 mL of dry dichloromethane and
0.05 mL of an azeotropic mixture of HCOOH:Et3N (5:2) . The mixture was stirred
for ten min. A solution of 3-(cyclopropylethynyl)-1,2-benzisothiazole 1,1-dioxide
(140 mg 0.606 mmol) in 1 mL dry dicholoromethane, and 0.05 mL of azeotrope
were added. The reaction was monitored by TLC. After 30 min, no product
formation was observed. Another aliquote of the azeotrope (0.1 mL) were
added, and the reaction mixture was stirred for another 30 min, and product
formation was observed at this time. Over the course of 2 h a total of 0.6 mL of
azeotrope was added, and TLC were taken at 15-min intervals. Upon
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disappearance of all starting material, the reaction was quenched with 1 M
NaHCO3 (aq.). The two layers were separated, and the organic layer was dried
over anhyd MgSO4, vacuum filtered and evaporated under reduced pressure to
give a dark-red residue. Purification by silica gel column chromatography in a
gradient solvent system from 5% acetone in pet ether15% acetone in pet ether
(this concentration was held until the first spot was isolated) 20% acetone in
pet ether (product eluted with this concentration) gave the desired product in
50% yield (70 mg). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.81–7.36 (4H, CH,
ArH), 5.45 (1H,s, NH), 5.13 (m,1H, CH, J = 3.9, J = 9.3, CH), 3.26–3.03 (m, 2H,
CH2(1′), J = 3.6 Hz, J = 9.6 Hz, Jgem= 18 Hz), 1.95 (m, 1H, CH in cycloropyl, J =
4.5, J = 1.5), 1.15–1.11 (m, 2H, CH2(2′),J = 4.5) 0.99–0.95 (dt, 2H, CH2 in
cyclopropyl, J = 3.6, J = 4.5), 0.89-0.84 (m, 2H, CH2 in cyclopropyl). 13C NMR
(300 MHz, CDCl3, 25 ºC): δ 138.61 (C-4, CH, Ar), 135.60 (C-9, Ar), 133.11 (C-6,
Ar), 129.36 (C-8, Ar), 123.88 (C-5, Ar), 121.55 (C-7, Ar), 52.90 (C-3), 48.95 (C1′), 21.06 (C-2′), 14 (CH, cyclopropyl), 11.71–11.61 (2CH2, cyclopropyl). HRMSAPPI (m/z): [M+H]+ calcd for C12H15NO2S, 238.0902; found, 238.0907.

3-(tert-Butylethynyl)-2,3-dihydro-1,2 benzisothiazole 1,1-dioxide (7)
In a dry round-bottom flask equipped with a stirring bar was dissolved 1.6 mg of
R,R-[TSDPEN]RhCp* in 1 mL of freshly dried dichloromethane and 0.047 mL of
HCOOH:Et3N azeotrope (1 equiv of formic acid to 1 equiv of catalyst) The
mixture was stirred for 10 min at room temperature, then a solution of 3-(tertbutylethynyl)-1,2-benzisothizole 1,1-dioxide, 120 mg (0.485 mmol) in 1 mL of
CH2Cl2 and 0.047 mL of azeotrope were added. The reaction was monitored by
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TLC, and after 30 min product was already forming. Over the course of 2.5 h a
total of 0.6 mL of azeotrope was added in increments of 0.1 mL at 30 min
intervals. TLC were taken every 15 min. At 2.5 h the TLC indicated completion of
the reaction. The reaction was quenched with 1 M NaHCO3 (aq). The biphasic
mixture was separated, and the organic layer was dried over anhyd MgSO4,
vacuum filtered and rotary evaporated to give a dark red-residue. Column
chromatography using a gradient solvent system starting with 5% acetone in pet
ether  15% acetone in pet ether (this was held until the first spot was
completely eluted) 20% acetone in pet ether until the desired product was
collected. Rotary evaporation gave the desired product as a white solid in 61%
yield (40 mg). 1H NMR (300 MHz, 25 ºC, CDCl3: δ 7.70–7.91 (m, 4H, CH, ArH),
6.2 (s,1H, CH), 1.25 (s, 9H, -C(CH3)).

13

C NMR : δ 151.00 (C-4), 135.42 (C-9),

133.42 (C-6), 133.09 (C-8), 129.92 (C-7), 122.65 (C7), 121.82 (C2′, C≡C), 89.54
(C1′, C≡C), 41.77 (C3), 27.04 (3 CH3, t-Butl), 0.98 (C3′, t-But). HRMS-APPI
(m/z): [M-H]+ calcd for C13H14NO2S, 248.074; found, 248.072.

3-(Cyclobutylethyl)-2,3-dihydro-1,2benzisothiazole 1,1-dioxide (23)
(R,R)-[TSDPEN]RhCp* (1.15 mg, 0.002 mmol) were dissolved in dry
dicholoromethane under anhydrous conditions and a nitrogen atmosphere. An
azeotropic mixture of HCOOH:Et3N (5:2) (0.034 mL) was added via a micro
syringe. The reaction was stirred for 10 min, then a solution of 3(cyclobutylethynyl)-1,2-benzisothiazole 1,1-dioxide (5) (89 mg, 0.36 mmol) in 1
mL of dichloromethane and 0.034 mL of azeotrope was added. Reaction
progress was monitored by TLC, and product started forming around 35 min.
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Over the course of 2.5 h 0.1 mL increments were added at 30-min intervals while
TLCs were taken every 15 min. Upon disappearance of all starting material, the
reaction was quenched with 1 M NaHCO3 (aq). The two layers were then
separated, and the organic layer was dried over anhyd MgSO4. It was then
vacuum filtered, and the solvent was removed under reduced pressure to give a
dark-red residue. Silica gel column chromatography using a gradient solvent
system from 5% acetone in petroleum ether to 15% acetone in petroleum ether
gave 79 mg (60%) of the desired product. 1H NMR (300 MHz, CDCl3, 25 ºC): δ
7.99–7.24 (4H, CH, ArH), 5.95 (1H,s, NH), 5.20 (m,1H), 3.95–3.1(m, 2H,
CH2(1′), 2.95 (m, 1H, CH in cyclobutyl) 2.1–1.1 (m, 4CH2, CH2(2′), 3CH2 in
cyclobutyl ). 13C NMR (300 MHz, CDCl3, 25 ºC): δ 138.61 (C-4, CH, Ar), 135.60
(C-9, Ar), 133.10 (C-6, Ar), 129.33 (C-8, Ar), 123.80 (C-5, Ar), 121.45 (C-7, Ar),
56.89 (C-3), 48.95 (C-1′), 21.06 (C-2′), 29.02 (CH, cyclobutyl), 19.42–18.16
(3CH2, cyclobutyll). HRMS-APPI (m/z): [M+H]+ calcd for C13H17NO2S, 251.098;
found, 250.969.

3-(Alkylethynyl)-2,3-dihydro-2-methyl 1,1-dioxide
The respective 3-(alkylethynyl)-2,3-dihydro-1,2-benisothiazole 1,1-dioxide was
dissolved in dry N-N-dimethylformamide or dry acetonitrile under anhydrous
conditions and a nitrogen atmosphere. Cs2CO3 (1.5 equiv) were added, and the
reaction mixture was then stirred at room temperature for 1 h. Excess amount of
MeI was added via a syringe, and the reaction was then stirred at room
temperature for 1 h. It was monitored by TLC (25% acetone in petroleum ether).
Upon disappearance of the starting material, the reaction was quenched with
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water. The mixture was concentrated under high vacuum to give a yellow oil with
a white precipitate. The residue was taken up in 5 mL dichloromethane and
washed with water (3 x 5 mL). The organic layer was then dried over anhydrous
MgSO4, and vacuum filtered, and the solvent was rotary evaporated under
reduced pressure to give a yellow oil. Flash column chromatography with 15%–
20% acetone in petroleum ether afforded the desired products in quantitative
yields.

3-(Cyclopropylethyl)-2,3-dihydro-2-methyl 1,1-dioxide (9)
Yield: 35 mg, 90% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.32–7.8 (m, 4H, CH,
ArH), 4.97–4.90 (t, 1H, CH(3)), 3.3-2.96 (m, 2H, CH2(2′), 2.90 (m, 3H, N–CH3),
2.0-1.9 (m, 1H, CH in cyclopropyl), 1.2–1.1 (m, 2H, CH2(2′)), 1.85–0.95 (m, 4H,
2CH2 in cyclopropyl). 13C NMR (300 MHz, CDCl3, 25 ºC): δ 138.13 (C-9, CH, Ar),
134.51 (C-6, Ar), 133.01 (C-7, Ar), 129.35 (C-5, Ar), 124.24 (C-4, Ar), 121.35 (C8, Ar), 58.64 (C-3), 47.46 (N-CH3), 29.59 (C-1′), 21.37 (C-2′), 18.00 (CH,
cyclopropyl), 11.71-11.61 (2CH2, cyclopropyl). HRMS-APPI failed after several
trials. Compound would not ionize.

3-(tert-Butylethynyl)-2,3-dihydro-2-methyl 1,1-dioxide(10)
Yield: 40 mg, 89% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 9.13-9.12 (d,1H, CH, Ar),
7.86-7.85 (m, 3H, CH, ArH), 6.13 (s,1H, CH(3), 10b), 5.91 (s,1H, CH(3), 10a),
3.21 (s, 3H, N-CH3, 10b), 3.18 (s,3H,N-CH3,10b), 1.2 (s, 9H, 3CH3, t-butyl).

13

C

NMR (300 MHz, CDCl3, 25 ºC): δ 133.87 (C-9), 133.57 (C-6), 132.17 (C-8),
129.00 (C-7), 122.65 (C7), 99.17 (C2′, C≡C), 94.73 (C1′, C≡C), 41.71 (C3 10a or

10b), 44.21 (C3, 10a or 10b), 29.69 (N-CH3) 27.12 (3 CH3, t-butyl), 0.98 (C3′, t142

butyl). HR MS-APPI (m/z): [M+H]+ Calcd for C14H16NO2S, 262.0902; found
262.0933.

3-(Cyclobutylethynyl)-2,3-dihydro-1,2-benzisothiazole (11).
Yield: 20 mg , 60%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.80–7.41 (4H, CH,
ArH), 5.20 (m,1H), 3.85–3.1(m, 2H, CH2(1′), 2.95 (m, 1H, CH in cyclobutyl),
2.89 (s, 3H, N-CH3) 2.1–1.1 (m, 4CH2, CH2(2′), 3CH2 in cyclobutyl ). 13C NMR
(300 MHz, CDCl3, 25 ºC): δ 137.61 (C-4, CH, Ar), 135.50 (C-9, Ar), 133.20 (C-6,
Ar), 129.33(C-8, Ar), 123.80 (C-5, Ar), 121.45 (C-7, Ar), 57.99 (C-3), 48.95 (C-1′),
21.06 (C-2′), 29.02 (CH, cyclobutyl), 19.42–18.16 (3CH2, cyclobutyll). APPI failed
after several attempts. The expected m/z of 280.137 was not observed, the
spectrum only had background.

2,3-Dihydro-3,3-dialkylethynyl-1,2-benzisothizoles 1,1-dioxide
Method A.
In a dry flask under anhydrous conditions and a nitrogen atmosphere were
dissolved 2.0 mmol of the respective alkyne. 1 equivilant of 2.2 M n-BuLi (0.9
mL) or 1.6 M MeLi (1.25 mL) were added via a syringe at -78 ºC. The reaction
was left to stir for four h while it warmed to -40 ºC. 0.9 mmol (0.165 g)of
saccharin (0.45 equivalents) were dissolved in dry THF and added dropwise over
a period of 30 min. The reaction was then left to warm up to r.t over night. It was
then cooled to 0 ºC and quenched with saturated NH4Cl (aq.). The biphasic
mixture was filtered, and the organic layer separated. It was washed with 1 M
NaHCO3 (2 x 5 mL) and dried over anhydrous MgSO4. Rotary evaporation
afforded the bis-alkylated sultam in low yields (15-30%yield).
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Method B.
In a dry flask under anhydrous conditions and a nitrogen atmosphere were
dissolved 2.0 mmol of the respective alkyne. 1 equivialnt of 2.2 M n-BuLi (0.9
mL) or of 1.6 M MeLi (1.25 mL) were added via a syringe at -78 ºC. The reaction
was left to warm to -40 ºC over the course of four h. A solution of 3-chloro-1,2benzisothizole 1,1-dioxide in THF (2 mmol, 0.402 g, 1 equivilant), were added
slowly over the course of 30-40 min at -78 ºC. The reaction was then left to
warm again to -40 ºC. It was then quenched with saturated NH4Cl (aq); the
mixture was filtered then separated. The organic layer was then washed with 1
M NaHCO3 (aq), then dried over anhydrous MgSO4. Vacuum filtration followed
by rotary evaporation gave the desired products as crystalline solids in moderate
yields.

2,3-Dihydro-3,3-dicyclopropyllethynyl-1,2-benzisothizoles 1,1-dioxide
(12)
Yield: 0.130 g, 60%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.74-7.754 (m, 4H, CH,
ArH), 5.0 (s, 1H, NH), 1.29-1.2 (m, 2H, 2CH from cyclopropyl), 0.81-0.68 (m, 8H,
4CH2 from cyclopropyl).

13

C NMR (300 MHz, CDCl3, 25 ºC): δ 140.97 (C-9, CH,

Ar), 134.26 (C-6, Ar), 133.63 (C-7, Ar), 130.36 (C-5, Ar), 125.21 (C-4, Ar), 121.21
(C-8, Ar), 88.76 (C-2′, C≡C), 72.39 (C-1′, C≡C), 52.27 (C-3), 8.37 (4CH2
cylopropyl), -0.59 (2CH cyclopropyl). HR MS-APPI (m/z): [M+H]+ calcd for
C17H16NO2S 298.0902, found 298.0906.

2,3-Dihydro-3,3-dicyclobutylethynyl-1,2-benzisothizoles 1,1-dioxide
(13)
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Yield: 0.150 g, 67% 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.76-7.55 (m, 4H, CH,
ArH), 3.09-2.90 (m, 1H, CH from cyclobutyl), 2.26-1.82 (m, 6H, 3CH2 from
cyclobutyl). 13C NMR (300 MHz, CDCl3, 25 ºC): 140.91 (C9, Ar), 134.03 (C-6, Ar),
133.37 (C-7,Ar), 130.09 (C-5), 124.98 (C-4,Ar), 120.95 (C-8,Ar), 89.09 (C-2′,
C≡C), 78.07 (C-1′, C≡C), 52.38 (C-3), 29.28-29.27 (2CH2, cyclobutyl ring), 24.61
(CH, cyclobutyl), 19.13 (CH cyclobutyl). HR MS-APPI (m/z): [M+H]+ calcd for
C19H20NO2S 326.1215, found326.1223. [M-H]+ calcd for C19H18NO2S 324.1058
found, 324.1471.

3,3-(di-tert-butylethynyl)-2,3-dihydro-1,2-benistohiazole 1,1-dioxide (14)
Yield: 0.110 9, 70%. 1H NMR (300 MHz, CDCl3, 25 ºC): δ 8.21-7.41 (m, 4H, CH,
ArH), 1.26 (s, 9H, t-butyl). 13C NMR (300 MHz, CDCl3, 25 ºC): δ 140.31 (C-4),
139.15 (C-9), 132.89 (C-6), 130.28 (C-8), 129.92 (C-5), 129.00 (C-7), 95.15 (C2′, C≡C), 79.69 (C-1′, C≡C), 66.14 (C-3), 30.29 (CH3, t-butyl), 27.58 (C-3′, tbutyl). HR MS-APPI (m/z): [M+H]+ calcld for C19H24NO2S 330.1528, found
330.1534.

2,3-Dihydro-2-methyl-3,3-(di-t-butylethynyl)-1,2-benzisothizoles 1,1-dioxide
(15)
In a flame dried flask 0.205 g (0.62 mmol) of (14) and 0.303 g (0.93 mmol, 1.5
equiv.) of Cs2CO3 were dissolved in freshly dried acetonitrile under anhydrous
conditions and a nitrogen atmosphere. The reaction was stirred at r.t. for one
hour then excess amount of MeI (0.1 mL, 3 mmol) were added via a syringe.
The progress of the reaction was monitored by TLC. Upon disappearance of the
starting material, the mixture was concentrated under reduced pressure to give a
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yellow oil and a white precipitate. The mixture was suspended in
dicholormethane and the organic layer was washed with water ( 3x 10 mL) and
dried over anhydrous MgSO4. Vacuum filtration, followed by rotary evaporation,
then high vacuum rotary evaporation gave a pale yellow oil. Flash column
chromatography with 15% acetone in petroleum ether afforded the desired
product in qualitative yield (0.200 g). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 8.367.4 (m, 4H, CH, ArH), 2.9 (s, 3H, N-CH3), 2.25 (s, 18H, 6CH3 t-butyl). 13 C NMR
143.03 (C-9), 137.12 (C-4), 132.41 (C-6), 129.92 (C-8), 129.54 (C-5), 128.55 (C7), 94.79 (C-2′,C≡C), 79.09 (C-1′,C≡C), 65.62 (C-3), 37.75 (N-CH3), 30.39 (C(CH3)3, 2 t-butyl), 27.49 (-C(CH3)). HRMS-APPI (m/z): calcd for C20H26NO2S
343.1606 found

2,3-Dihydro-2-methyl-3,3-(dicyclobutyllethynyl)-1,2-benzisothizoles 1,1dioxide (16).
In a dry round-bottom flask 83 mg (0.255 mmol) and 125 mg (0.383 mmol , 1.5
equiv.) were dissolved in dry acetonitrile under anhydrous conditions and a
nitrogen atmosphere. The mixture was stirred at r.t. for one hour, then an excess
amount of MeI (108 mg, 0.048 mL, 3 equiv) were added via a syringe. The
reaction was monitored by TLC. Upon disappearance of starting material, it was
rotarty evaporated to give a yellow oil and white precipitate. The residue was
taken up in 10 mL of dichloromethane and washed with water (3 x 5 mL). The
organic layer was then collected, dried over anhydrous MgSO4 and vacuum
filtered. It was concentrated under reduced pressure and high vacuum pressure
to give a pale yellow crystalline solid. Flash chromatography using 15% acetone
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in petroleum ether gave the desired product in quantitative yield as a while
crystalline solid (85 mg). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.78-7.75 (4H,
CH, ArH), 3.07-2.81 (m, 2H, 2CH from cyclobutyl), 2.99 (s, 3H, CH3), 2.26-1.83
(m, 12H, 3CH2) from cyclobutyl). HRMS-APPI(m/z): [M+H]+ calculated for
C20H22NO2S 339.1293, found 339.1298

3,3-(Dicyclopropylethynyl)-2,3-dihydro-2-methyl-1,2-benzisothizoles 1,1dioxide (12)
In a flame dried round-bottom flask 89mg (0.329 mmol) and 161 mg (0.495 mmol
, 1.5 equiv.) were dissolved in dry acetonitrile under anhydrous conditions and a
nitrogen atmosphere. The mixture was stirred at r.t. for one hour, then an excess
amount of MeI (108 mg, 0.048 mL, 3 equiv) were added via a syringe. The
reaction was monitored by TLC. Upon disappearance of starting material, it was
rotarty evaporated to give a yellow oil and white precipitate. The residue was
taken up in 10 mL of dichloromethane and washed with water (3 x 5 mL). The
organic layer was then collected, dried over anhydrous MgSO4 and vacuum
filtered. It was concentrated under reduced pressure and high vacuum pressure
to give a pale yellow crystalline solid. Flash chromatography using 15% acetone
in petroleum ether gave the desired product in quantitative yield as a while
crystalline solid (160 mg). 1H NMR (300 MHz, CDCl3, 25 ºC): δ 7.64-7.44 (m, 4H,
CH, ArH), 2.98 (s, 3H, N-CH3) ,1.91-1.21 (m, 2H, 2CH from cyclopropyl), 0.810.68 (m, 8H, 4CH2 from cyclopropyl).

13

C NMR (300 MHz, CDCl3, 25 ºC): δ

140.87 (C-9, CH, Ar), 134.16 (C-6, Ar), 133.63 (C-7, Ar), 130.36 (C-5, Ar), 125.11
(C-4, Ar), 121.21 (C-8, Ar), 88.76 (C-2′, C≡C), 72.39 (C-1′, C≡C), 55.27 (C-3),
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30.41 (N-CH3) 8.37 (4CH2 cylopropyl), -0.59 (2CH cyclopropyl).HRMS-APPI
(m/z): [M+H]+ calcd for 340.1293 found 340.1299
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